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Abstract 
Ovarian carcinogenesis is believed to be a multi-step process which 
involves multiple genetic changes. Alterations in gene expression therefore play 
important roles in ovarian tumor formation. DOC-2, one of the differentially 
expressed genes in ovarian tumors, has been proposed to be a tumor suppressor. 
Li the present study, inununohistochemical examinations on different types of 
human ovarian tissues showed that the expression of DOC-2 protein was high in 
normal ovaries, benign and borderline tumors but was significantly down-
regulated in invasive tumors. Up-regulation of DOC-2 protein expression in 
ovarian carcinoma cell lines by transfection of the full-length DOC-2 gene into 
the cell lines significantly reduced the growth rate of the cancer cells. Elevated 
expression of DOC-2 protein in the cell lines suppressed the tumor formation in 
athymic nude mice. Sequence analysis by other studies revealed a 
phosphotyrosine interaction domain in the protein which is suspected to be 
involved in signal transduction and embryonic development, 
inmunohistochemical studies of mouse embryos showed that DOC-2 protein 
was expressed in the embryonic brain, cartilages and kidney. Depletion of 
DOC-2 protein by addition of an anti-DOC-2 antibody in organ culture 
decreased the size of the kidney developed in vitro. 
Alterations in p53 and bcl-2 expression and apoptosis were also 
examined in different types of human ovarian tissues. Results showed that bcl-2 
protein was expressed in normal ovaries, benign and borderline tumors but its 
expression was down-regulated in invasive tumors, whereas p53 over-expression 
was observed only in invasive tumors, bcl-2 and p53 expression showed an 
inverse correlation in invasive tumors. Apoptosis as detected by TUNEL was 
however high in invasive tumors but did not show any relationship with bcl-2 
and p53 expression. 
The present study showed that DOC-2 protein expression was down-
regulated in human invasive ovarian tumors and that up-regulation of DOC-2 
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protein led to inhibition of tumor growth both in vitro and in vivo. Expression of 
DOC-2 protein in various embryonic tissues indicated that the protein may 
involve in embryonic development, p53 and bcl-2 expression, which may not be 
directly involved in the regulation of apoptosis in ovarian tumors, was inversely 
correlated in invasive ovarian tumors. Despite the expression patterns of DOC-2 
and bcl-2 were similar in ovarian tissues, their relationships in ovarian 
carcinogenesis remains to be elucidated. 
(Part of the results described in the present study have been presented in the 88th 
Annual Meeting of the American Association for Cancer Research on 12th to 
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Chapter I Introduction 
Chapter 1. General introduction of human ovarian cancer 
1.1 Epidemiology 
Ovarian cancer, being the seventh most common cancers in women 
worldwide after breast, cervix, colon/rectum, stomach, corpus uteri, and lung 
cancers, showed the highest incidence rates in developed countries (except 
Japan) and the lowest in developing countries (Tortolero-Luna and Mitchell, 
1995). According to the survey done by the American Cancer Society in 1995, 
26,600 cases of ovarian cancer were diagnosed in the United States and 
approximately 14,500 women died of the disease, which was the leading cause 
of death from gynecologic malignancies. Although ovarian cancer accounted 
i 
for only 5% of all cancer cases and, specifically, 33% of the gynecologic 
cancers, it resulted in 55% of the deaths from the disease. Ovarian cancer was, 
thus, the fourth leading cause of cancer death in women, being preceded by 
lung, breast, and colorectal cancer (Wingo et al., 1995). 
The incidence rates for ovarian cancer show a wide geographic variation. 
The highest rates are observed in highly industrialized countries such as 
Scandinavian countries (2.12% in Sweden; 2.03% in Denmark and 1.87% in 
Norway), Switzerland (1.91%), Federal Republic of Germany (1.81%), Israel 
(1.66% for those who bom in either United States or in Europe) and North 
America (e.g., 1.64% in Iowa), whereas Japan (0.43%) and developing 
countries (e.g., 0.47% in China) show the lowest incidence rates (Piver et al., 
~~ 1 
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1993). Such incidence of ovarian cancer has remained stable over the last 
three decades in high-risk countries, while a trend to increasing incidence has 
been reported in low-risk countries (Parazzini et al., 1991). Jn the United 
States, incidence rates are high among white and Hawaiian women, 
intermediate among African-American, Hispanic, and Asian women, and 
lowest among Native American women (Tortolero-Luna and Mitchell, 1995). 
For the period of 1986-1990，the incidence rate among white was 50% higher 
than among African-American (15 per 100,000 women versus 10.2 per 
100,000 women) (Tortolero-Luna and Mitchell, 1995). Ovarian cancer, on the 
other hand, shows an age-specific incidence in the United States in which it 
rises from about 2 per 100,000 at age 20 to about 50 per 100,000 in women at 
age 65. Ovarian cancer is rare before age 40 but increases sharply, and peaks 
at about age 65 to 70 and thereafter remains stable (Brinton and Hoover, 
1992). 
ln England, Wales and the United States, mortality of patients suffered 
from ovarian cancer increases with each successive cohort bom after 1861. 
The mortality peaks among women bom in the early 1900s，and then declines 
with each successive generation (Devesa et al., 1987; Villard-Mackintosh et 
al., 1989). The increasing trend in mortality from ovarian cancer has slowed 
down since the mid-1970s. This trend is mainly due to a decline in mortality 
among women under age 55 and coincides in time and magnitude with the use 
of oral contraceptives. During the last twenty years, the overall age adjusted 
mortality rate from ovarian cancer declined approximately 7% in the United 
-
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States. However, the decrease in mortality has been limited exclusively to 
women under 50 years old (40% reduction). The overall age-adjusted 
mortality rate for the period 1986-1990 was 7.8/100,000，and it was slightly 
higher among whites (8.0/100,000) than among African-Americans 
(6.4/100,000). 
One of the reasons for ovarian cancer being the leading cause of cancer 
death among the gynecologic cancers is mainly attributed to the difficulties for 
early diagnosis. While 73% of endometrial cancers, 55% of breast cancers and 
50% of cervical cancers are diagnosed as Stage I, only 23% of ovarian cancer 
are diagnosed as Stage I (Wingo et al., 1995). Actually, over 75% of ovarian 
cancer cases are diagnosed when the disease is already in advanced stages 
(Miller et al., 1993). The cure rate for ovarian cancers localized to the ovary 
(Stage J) is about 90%. However, the cure rate for the advanced stage of 
ovarian cancer (Stage m and JV) is only 29% (Wingo et al., 1995). These data 
account for the low survival rates for ovarian cancer in which five-year 
survival for all endometrial cancer is 85%, for all breast cancer, 82%, for 
cervical cancer, 70%, but for ovarian cancer, only 42% (Wingo et al., 1995). 
-
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1.2 Symptoms and diagnosis 
Ovarian cancer, as mentioned before, is often asymptomatic in its early 
stages and most of the patients with ovarian cancer present with advanced 
stages of the disease at the time of diagnosis. Symptoms occur only when the 
ovarian mass begins to encroach on other viscera or when there is intra-
abdominal spread. In most cases at that time, patients report vague abdominal 
pain, abdominal swelling, dyspepsia increased, urinary frequency, constipation 
and weight change. Sometimes patients may also find pelvic discomfort, low 
back pain and vaginal bleeding (Piver et al., 1993). 
Despite the absence of early symptoms, there are no proven screening 
tests for ovarian cancer. The most commonly used diagnostic methods are 
ultrasonography, computed tomography (CT), magnetic resonance imaging 
(MRI), and radiolabelled monoclonal antibody imaging (e.g. CA125 assay). 
Unfortunately, they are not specific enough to distinguish between benign and 
malignant ovarian tumors. Ultrasonography, although it is 80 to 90% accurate 
in assessing the size, location, and consistency of ovarian tumors, usually gives 
false-positive diagnosis. Li a study done by Goldstein et al. (1989), 26 women 
between ages 46 and 86 with ovarian cysts were undergone laparotomy based 
on the diagnosis of ultrasonography and all were found to have benign 
histopathology. Similar studies were also done by Rulin and Preston (1987) 
and Flynt and Gallup (1981) and both concluded that the percentage of ovarian 
cancer being detected was far lower than expected from the study of 
-
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ultrasonography. Li contrast, the results of computed tomography may provide 
high false-negative rates (Clarke-Pearson et al., 1986) and the drawbacks of 
the technique include radiation exposure, lack of clarity and details in obese 
and very thin patients, and the small risk of a reaction to the contrast media 
(Piver et al., 1993). Although magnetic resonance imaging (MRI) can 
distinguish between normal and abnormal structures, it cannot differentiate 
between benign and malignant masses. Moreover, a lack of bowel contrast 
agents makes it difficult to distinguish disease of the gastrointestinal tract from 
ovarian masses (Piver et al., 1993). CA125, used in CA125 assay, is a high 
molecular weight glycoprotein with antigenic determinants recognized by the 
murine monoclonal antibody OC125. CA125 was low in normal adult ovaries 
but elevated in patients with epithelial ovarian cancer (Bast et al., 1983). 
However, level of CA125 are also elevated after laparotomy as well as in 
several nonmalignant conditions, such as menstruation, early pregnancy, 
endometriosis, pelvic inflammatory disease, hepatitis, pancreatitis, peritonitis 
and renal failure (Piver et al., 1993). Furthermore, the immune response, the 
rapid clearance of mouse monoclonal antibodies, and the overall sensitivity 
and specificity rates have prevented the widespread clinical use of the 
technique in the early diagnosis of ovarian cancer (Piver et al., 1993). 
1.3 Etiology 
Although the etiology of ovarian cancer still remains unknown, several -
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factors have been consistently associated with decreased or increased risks of 
the disease. 
1.3.1 Factors associated with decreased risks 
Pregnancy. Pregnancy has been associated with a lower risk of ovarian 
cancer. These findings were obtained by the pooled analysis in United States 
(Whittemore et al.，1992), Europe (Negri et al., 1991)，Canada (Risch et al., 
1994) and Sweden (Adami et al., 1994). There is a theory proposed by Fathala 
(1971) named "incessant ovulation theory". According to the theory, the 
development of crypts and inclusion cysts in the ovarian stroma may be due to 
continuously repeated traumatization of the superficial epithelium and repair 
of the surface defect (Radisavljevic, 1977; Zajicek, 1978). These ruptures are 
then repaired by cell division. Such traumatization may cause the mutation of 
genes involving in regulation of growth of surface epithelium. It was proposed 
that these repeated episodes of proliferation may provide cells already bearing 
allelic loss and those carrying inactivated tumor suppressor genes with chances 
to increase their cell numbers. This may lead to uncontrolled cell division and 
malignant transformation. Therefore, pregnancy provides a rather long period 
of time for the surface epithelial cells to take a rest by ceasing ovulation. 
Oral contraceptives (OCs) OCs have been shown to be associated with up to 
70% reduction in risk in people who use OCs for 10 or more years compared 
with those who never-use (Hankinson et al., 1992). The protection 
presumably, like pregnancy, reflects long-term suppression of ovulation. The 
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effect of OCs is one of the best established and the most consistent finding in 
epidemiology of epithelial ovarian tumors. According to the studies done 
separately by the Cancer and Steroid Hormone Study of the Centers for 
Disease Control and the National Institute of Child Health and Human 
Development (1987), and the World Health Organization (WHO) 
Collaborative study of Neoplasia and Steroid Contraceptives (1989)，epithelial 
ovarian cancer risk decreases with increasing duration of OC use. A consistent 
and clear reduction of risk are observed after five or more years of OC use. 
Such protective effects of OCs appear to persist for a long period of time (up 
to 10 or more years) after discontinuation of OC use (Hankinson et al., 1992). 
Tubal Ligation and Hysterectomy Tubal ligation and hysterectomy with 
ovarian conservation have been associated with a decreased risk of ovarian 
cancer. Whittemore et al. (1992) estimated a 40% reduction in hospital-based 
studies and a 13% reduction in population-based studies in invasive epithelial 
ovarian cancer risk associated with tubal ligation. Hysterectomy with ovarian 
conservation has also shown an inverse association with ovarian cancer risk in 
several studies (t*win et al., 1991; Weiss and Harlow, 1986). The inverse 
association may be explained in the way that tubal ligation and hysterectomy 
block the ascent of carcinogenic agents such as asbestos, viruses, or 
contraceptive foams or gels into the peritoneal cavity. 
Breast feeding Women with a history of breast feeding are reported to have a 
lower risk of ovarian cancer than nulliparous women and parous women who 
have not breast fed. Women who have breast fed have a 60% decrease in risk 
_ -
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compared with nulliparous women, and parous women who have breast fed 
have a 40% decrease in risk of getting ovarian cancer compared to parous who 
have not breast fed (Schneider, 1987). Whittemore et al. (1992) reported that 
there was a decrease in risk of ovarian cancer with increasing duration of 
breast feeding. They estimated that the risk decreases 0.99 with every month 
of breast feeding. Jn addition, the reduction in risk conferred by breast feeding 
is larger in the first six months after delivery than the reduction observed with 
subsequent months of lactation. 
1.3.2 Factors associated with increased risks 
Family History Epithelial ovarian cancer can occur as a sporadic event in 
women who have no family history of ovarian neoplasia but several clinical 
and epidemiological studies have shown women who do have a family history 
are at increased risk of suffering from ovarian cancer. Lynch et al. (1990) have 
estimated that approximately 5-10% of ovarian cancer may be due to 
hereditary factors. Three hereditary syndromes in which familial aggregation 
of ovarian cancer occur have been described by Lynch et al. (1993) as the site-
specific ovarian cancer syndrome, the breast-ovarian cancer syndrome, and the 
hereditary non-polyposis colorectal cancer syndrome (Lynch Syndrome H) and 
these three hereditary syndromes are associated with a significantly earlier 
onset of disease than is usually seen in patients without family histories (Lynch 
et al., 1991). Schildkraut and Thompson (1988) determined the magnitude of 
association for ovarian cancer in first-degree relatives was higher than that in 
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second-degree relatives, compared with females without family history of 
ovarian cancer. The magnitude of the association was similar for all major 
histologic subtypes (serous, mucinous, and endometrioid, see chapter 1.4). Li 
the same study, they also compared family history of epithelial ovarian cancer 
with the risk of borderline ovarian tumors and they found that some of 326 
patients with malignant ovarian tumors reported a family history of ovarian 
cancer in a first-degree relatives. In contrast, none of 123 patients with 
borderline ovarian tumors reported positive family histories of ovarian cancer. 
It is suggested that the malignant and the borderline ovarian tumors may be 
two different etiologic entities. Similar findings were also observed by 
Harlow et al. (1988) which indicated that family history does not appear to be 
a risk factor for borderline ovarian tumors. Etiologically, women with ovarian 
cancer represent a heterogeneous group including women whose genetic 
makeup predisposes them to ovarian cancer, whose lifestyles may have 
contributed to their ovarian carcinogenesis，or both. It is suggested that some 
ovarian cancers may arise through processes that are not familially shared, and 
the relatives in these cases may not be at an increased risk, whereas some arise 
through processes that are familially shared, and the relatives of these patients 
are at an increased risk. However, the details about the interactions between 
the genetic component and the environmental influences are still unknown 
(Lynch et al., 1993). Despite current evidence, the occurrence of familial 
cancer accounts for only a small proportion of ovarian cancer cases, which 
were demonstrated by Parazzini et al. (1992) and Schildkraut and Thompson 
-
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(1988). These data suggested that although family history increases the risk of 
malignant ovarian cancer, there are still other factors which are also 
responsible for ovarian carcinogenesis. 
Dietary factor The major dietary difference between people living in 
industrialized and non-industrialized countries is the high intake of red meat 
and animal fat by the people in industrialized countries, and such difference 
may attribute to the difference in incidence of ovarian cancer between these 
two different types of countries. For example, Sweden, which is well known 
of having a high incidence of ovarian cancer, have higher per-capita animal fat 
consumption than countries with lower per-capita fat consumption such as 
Japan and China (Li and Shiang, 1980; Cramer et al., 1984; Rose et al., 1986). 
Li a case controlled study done by Cramer et al. (1989)，the incidence of 
ovarian cancer was threefold higher in women who consumed significantly 
more yogurt and cottage which have considerable levels of lactose. On the 
other hand, the serum levels of galactose-1 -phosphate uridyltransferase were 
significantly lower among patients with ovarian cancer compared with the 
control groups. Based on these findings, the authors proposed that populations 
that consume a high fat-galactose diet but lack the enzyme galactose-1-
phosphate uridyltransferase to breakdown galactose to glucose may result in 
overexposure of ovary to increasing levels of galactose. Mettlin and Piver 
(1990) also evaluated the association between ovarian cancer and animal fat 
content in milk. Li their study using 303 patients with ovarian cancer and 606 
patients with nonmalignant disease, the relative risk for ovarian cancer was 3.1 
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for those who drank more than one glass of whole milk each day compared 
with those who never drank whole milk. Among patients who drank milk 
regularly, those who drank only whole milk were at increased risk compared 
with those who drank milk with 0% or 2% milk. 
Infertility and Fertility Drugs Although results from studies linking infertility 
and use of fertility drugs with the incidence of ovarian cancer are far less 
consistent compared with the hereditary factor, recent publications 
(Whittemore et al., 1992; Rossing et al., 1994; Venn et al., 1995; Harris et al., 
1992) did show the association. Whittemore et al. (1992) found a non-
statistically significant increased risk for ovarian cancer among ever-married 
nulliparous women who had clinically diagnosed of infertility. Rossing et al. 
(1994) also observed an increase in ovarian cancer among a cohort of infertile 
women. Venn et al. (1995) found that women with unexplained infertility had 
significantly increased risk of ovarian cancer. On the other hand, Both Harris 
et al. (1992) and Rossing et al. (1994) reported that there was an increased 
association between the use of fertility drugs and the incidence of borderline 
ovarian tumors. However, Venn et al. (1995) found no evidence on the 
association for borderline ovarian tumors. Whittemore et al. (1992) also 
observed that infertile women treated with fertility drugs were at high risk of 
ovarian cancer compared to women without a history of infertility, whereas 
infertile women who did not use fertility drugs were not at increased risk, 
suggesting a role of fertility drugs in the etiology of ovarian cancer. 
~ u 
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1.4 Classification of ovarian cancer 
According to the World Health Organization ‘ s (WHO) Classification 
based on the histological findings, human ovarian tumors can be classified into 
three predominant classes~common epithelial tumors (adenocarcinomas), 
germ cell tumors (derived from oocytes), and sex cord-stromal tumors (derived 
from the sex cord and stromal elements of the embryonic gonad). Apart from 
these three major classes, there are still some minor ovarian tumors in which 
either their histogenesis is undetermined, their histology is non-specific, or 
they are metastatic to the ovary. Common epithelial tumors, which are the 
most commonly diagnosed ovarian tumors, account for approximately 90% of 
ovarian tumors. While germ cell and sex cord-stromal tumors account for 5% 
each. Since common epithelial ovarian tumors are the most predominant class 
and the specimens studied in this report are of such histological type, only the 
pathology of common epithelial ovarian tumors are discussed in this section. 
Common epithelial ovarian tumors are believed to derive from the surface 
epithelial cells lining the outside of the ovary, either arising directly from that 
epithelium or from epithelial fragments invaginated into the underlining 
connective tissue (stroma) to form inclusion cysts. On occasion, the surface 
epithelial cells may proliferate with or without underlying stromal response, 
and form a surface papillary structure either composed of, or covered by 
epithelium varying from benign to malignant (invasive) tumors. The ovarian 
surface epithelium is the adult derivative, and direct descendant, of the 
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coelomic epithelium which, during embryonic life, overlies the nephro-genital 
ridge and from which are derived from the Mullerian ducts. It is thought that 
undifferentiated cells in the surface epithelium of the postnatal ovary retain a 
latent capacity to differentiate along the same pathways as do their embryonic 
precursors, and hence a neoplasm derived from these cells can differentiate 
along various Mullerian pathways. Consistent with the Mullerian 
differentiation of the epithelial surface during the transformation to neoplasia, 
there are five major histological subtypes of common epithelial tumors namely 
serous (50%), which are histologically similar to fallopian tube epithelium; 
endometrioid (15%), which are similar to endometrial epithelium; mucinous 
(10%), which are similar to endocervical epithelium; clear cell (5%) which are 
similar to endometrial epithelium during pregnancy; and Brenner (1%); which 
are similar to urothelial epithelium. Approximately 20% of epithelial ovarian 
cancer are undifferentiated and cannot be categorized. There are also mixed 
epithelial tumors consisting of components of more than one histological cell 
type. 
Serous tumors The epithelium of serous tumors varies from flat to tall 
columnar type, sometimes with cilia, resembling fallopian tube epithelium. 
Serous tumors are often accompanied with calcified granules (psammoma 
bodies) which appear to result from degeneration of small papillae. A small 
proportion of serous tumors are entirely exophytic and are designated surface 
papillary serous tumors. 
Endometrioid tumors ln 1961，the Cancer Committee of the titemational 
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Federation of Gynecologists and Obstetricians meeting established the term 
��endometrioid" tumors to differentiate from the endometrial adenocarcinomas 
which share the same histology. The epithelium consists of oval or round 
branching glands lined by tall columnar epithelium with dense nuclei. 
Mucinous tumors Mucinous tumors are lined by small columnar epithelium 
with basal nuclei and mucinous eosinophilic cytoplasm resembling 
endocervical epithelium. Occasionally, goblet cells, argentaffin cells and 
Paneth cells are present in some mucinous tumors. 
Clear cell tumors Clear cell tumors are lined by flattened or cuboidal 
polyhedral cells with clear cytoplasm. Often, cells with nuclei protruding into 
the glandular lumen (hobnail cells) are present. More often than any other 
tumors, clear cells tumors are associated with endometriosis. 
Brenner tumors Brenner tumors consist of small islands of transitional 
epithelium in abundant fibrous stroma. Unlike other epithelial ovarian tumors, 
over 99% of Brenner tumors are benign forms. Histologically, the rare 
borderline Brenner tumors are similar to noninvasive, grade I papillary 
transitional carcinoma of the urinary bladder. 
Each of the five epithelial tumors subtypes can all exist in benign, 
borderline or malignant forms. Benign epithelial tumors are often associated 
with epithelial inclusion cysts. Such tumor types are found in women of all 
ages, from infancy to the late postmenopausal years, but are most prevalent 
during the reproductive years. They are most commonly unilateral. 
Microscopic examinations of the tumors show that there are papillary 
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structures protruding into the cystic cavity which is lined by a single layer of 
epithelial cells resembling the ovarian surface epithelium. The epithelial cells 
are cuboidal, often columnar, displaying various metaplastic cells such as 
ciliated, mucus secreting, hobnail, or clear cells. The nuclei are round or oval, 
and regular, with a finely distributed chromatin pattem. The cystic tumors are 
multilobular and may reach very large sizes (up to 50cm in greatest diameter) 
and most of them are of mucinous subtypes. However, some benign epithelial 
tumors e.g. endometrioid subtypes, display branching tubular glands which are 
lined by columnar epithelium resembling that of endometrial glands. 
Another form of tumor subtype is the epithelial ovarian tumors of low 
malignant potential (or borderline ovarian tumors). The borderline tumors 
were first reported by their distinctive features which were neither benign nor 
malignant. Li 1961，the Litemational Federation of Gynecologists and 
Obstetricians (FIGO) acknowledged the importance of this intermediate group 
of epithelial tumors and suggested a system that subdivides ovarian tumors 
into benign cystadenomas, cystadenocarcinomas of low malignant potential, 
and cystadenocarcinomas. Li 1973, the World Health Organization (WHO) 
adopted a classification of epithelial tumors. About 10-15% of all common 
epithelial ovarian tumors are classified as borderline. They are characterized 
by an unusual degree of epithelial cell stratification, high mitotic activity, 
nuclear atypia, but lack evidence of stromal invasion. The borderline tumors 
occur in younger patients, and the survival rates of such patients are 
significantly better than patients with malignant tumors (Harlow et al., 1987). 
_ 
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Microscopic studies show that the tumors consist of changes in 
cytoarchitecture, cytological appearance, and proliferative pattern. There is 
epithelial budding of papillary structures forming patches of cell clusters that 
often detach into the cystic space. The piling up of epithelial cells may reach 
up to nine layers. Cytologically, the nuclear/cytoplasmic ratio are increased. 
Nucleoli and chromatin patterns are prominent. Characteristically, there is no 
stromal invasion and the stroma is composed of dense mature connective 
tissue. 
The epithelial malignant tumors of the ovary represent almost 90% of all 
ovarian malignancies. The malignant forms of ovarian tumors are metastatic 
and, unlike borderline ovarian tumors, show stromal invasion. The high 
mortality of patients with ovarian tumors is because the great majority are 
diagnosed in stage HI or IV (see chapter 1.4.1), when the ovarian tumors have 
spread to the peritoneal cavity. The most common causes of death of patients 
are respiratory failure (43%) and infection (12%) (Rose et al., 1989). The 
predominant features of the malignant tumors are papillary structures 
composed of a fibrovascular stalk that may range from irregular coarse to 
slender and delicate. 
Staging 
The function of staging system for any type of cancers is to reflect the 
biological behavior of the specific cancer by classifying patients into 
prognostic subgroups based on the extent of tumor spreading of the disease 
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and other factors. Accurate staging also provides advantages for treatment 
planning and facilitates the comparison of data between institutions. When 
confronted with an ovarian mass, the surgeon must prepared to perform an 
ovarian cancer staging operation. However, clinical signs and symptoms are 
notoriously misleading and often underestimate the true extent of disease. For 
example, other cancers and nonmalignant conditions such as fibromas, 
endometrioisis, or tuberculosis show similar signs and symptoms of ovarian 
cancer (Moore,1993). Li 1987，the Litemational Federation of Gynecology and 
Obstetrics (FIGO) adopted a revised staging system for ovarian cancer (Table 
1) which took into account multiple prognostic variables such as tumor 
distribution and volume, tumor rupture, malignant cytology and lymph node 
metastasis, while histological type, tumor grade, DNA content, hormone 
receptor status, and residuum after cytoreductive surgery are not considered in 
FIGO staging (Moore, 1993). 
Grading 
Tumor grade is an essential prognostic variable with regard to response to 
therapy and disease-free survival in malignant ovarian tumors. Practically, 
pathologists employ an architectural grading system adopted by the 
titemational Federation of Gynecology and Obstetrics (FIGO) that is based 
upon the glandular pattem of the ovarian tumors. Grade I carcinomas are well-
differentiated and are predominantly glandular. Grade H carcinomas are 
moderately differentiated and are 50% glandular, while grade HI carcinomas 
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are poorly differentiated and are predominantly solid. The degree of 
differentiation is related to the proportion between epithelial and connective 
tissue (the more epithelial, the more the differentiation) and to the cellular 
atypia. The Gynecologic Oncology Group (GOG) classification of epithelial 
ovarian cancer takes into account both FIGO staging and histological grading 
system to divide the ovarian tumors into early and advanced epithelial ovarian 
tumors and to distinguish between low risk group and high risk group among 
early diseased patients (Hoskins, 1993). 
1.5 Molecular basis of ovarian cancer 
Although the exact etiology of ovarian cancer remains unknown, it is 
generally believed that cancers are derived from a single cell that acquires an 
accumulation of a series of unrepaired genetic defects. The cell becomes less 
responsive to growth-inhibiting signals and undergoes unscheduled cell 
division (Cavenee and White, 1995). Likewise, the development of ovarian 
neoplasm may result from certain irreversible genetic changes. Jacobs et al. 
(1992) and Mok et al. (1992) reported that more than 90% of cases of 
epithelial ovarian cancers are clonal diseases that arise from a single cell. 
Multiple genetic alterations must occur during the malignant transformation of 
a single ovarian surface epithelial cell (Bast et al., 1995). Jn order to identify 
genes that are involved in ovarian carcinogenesis, association between ovarian 
cancer and chromosomal aberrations is the most preliminary but indispensible 
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step. The first association between a particular chromosomal abnormality and 
a human cancer was made in 1960，which led to the discovery of the 
arrangement involving chromosome 9 and 22 contributing to the development 
of leukemia (reviewed by Gilbert, 1993). Current molecular approaches that 
are principally related to the detection of cytogenetic deletions or 
translocations include the loss of heterozygosity (LOH) (Gilbert, 1993). LOH 
is currently used to assess at the molecular level the loss of chromosome-
specific markers that are present in the genome of normal cells from the same 
persons (Gilbert, 1993). Li ovarian cancer, a high frequency of LOH had been 
detected on chromosome 3p, 6p-q, l lp , 17p-q, 19p, 22q and Xp while other 
chromosomal regions have variable frequencies of LOH between 20-25% 
(reviewed by Amfo et al., 1995). Chromosomal abnormalities unique to, or 
frequently found in, particular cancers are postulated to be related to the locus 
of gene involved in tumor development. Lidividual chromosomes, though 
small, accommodate hundreds to many thousands of genes (of the total of 
50,000 to 100,000 genes in the haploid genome) (Gilbert, 1993). 
Epidemiological studies indicated that the process of ovulation may play an 
important role in ovarian carcinogenesis (Fathalla，1971). During each 
menstrual cycle, oocytes undergo a continuous process of maturation. Li the 
middle of the cycle, a matured oocyte is ovulated and the surface epithelium of 
the ovary is ruptured. The ovarian surface epithelial cells will then undergo 
several cycles of cell division to have the wound heal up in the epithelial 
surface. This healing process may allow chances for the development of 
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epithelial inclusion cysts and malignant tumors probably arise from them 
(Huston et al., 1995). The process of cell division, which in tum leads to DNA 
replication (S phase), makes the genes more susceptible to genetic mutations 
than when the cells are at resting stage (Bast et al.,1995). Under normal 
situations, the proliferation of ovarian surface epithelial cells is controlled by a 
series of growth regulatory genes. When the genes that regulate growth and 
proliferation become abnormal or mutated, carcinogenesis ensues. Generally, 
two classes of genes have been implicated in carcinogenesis, namely 
oncogenes and tumor suppressor genes. 
Oncogenes 
Oncogenes are considered dominant transforming genes as activation due 
to alterations in only a single allele of the gene can cause cell transformation. 
Activation of oncogenes can occur through a variety of mechanisms e.g. 
mutation, amplification, translocation and deletions. The largest family of 
oncogenes for ovarian carcinogenesis are the tyrosine kinases, which catalyse 
the transfer of a phosphate group from ATP to tyrosine residues of specific 
cellular proteins (Berchuck and Bast, 1993). Two types of tyrosine kinases 
have been described. They are either the cell surface receptors for growth 
factors or intracellular kinases (Katso et aL, 1997). The growth factor 
receptors have a conserved primary structure which consists of an extracellular 
ligand binding domain, a transmembrane segment, a juxtamembrane portion 
and an intracellular catalytic domain. Specific growth factors have been 
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identified for individual receptors, such as epidermal growth factor (EGF) and 
its family, platelet derived growth factor (PDGF), fibroblast growth factor 
(FGF) and its family, insulin-like growth factors (IGFs), macrophage colony-
stimulating factor (M-CSF) and transforming growth factors-P (TGF_P) and its 
family (Berchuck and Bast, 1993). Li general, the growth factors bind to their 
specific receptors on tyrosine residues. Such phosphorylation then transmits 
signals through specific pathways to the nucleus to stimulate transcription. 
Most often the pathway involves adaptor proteins, src homology 2 and 3 (SH2, 
SH3) domain containing proteins, SOS, SHC, raf, ras, and the mitogen 
activated kinases (Map kinases) (Pawson and Schlessinger, 1995). C-erbB 1, 
HER-2/neu, c-fms are examples of genes that encode growth factor receptors 
(Katso et al., 1997). Several lines of evidence have implicated such growth 
factors in ovarian carcinogenesis. Mills et al. (1988) showed that the growth 
factors present in the ascites of patients with ovarian cancer stimulate 
proliferation of both fresh ovarian cancer cells and ovarian cancer cell lines. 
Li addition, it is the presence of ovarian cancer ascites, but not the benign 
ascites, that supports the growth of ovarian cancer cell line in nude mice (Mills 
et al., 1990). The second class of tyrosine kinases is found anchored to the 
inner surface of the cell membrane and they also phosphorylate cellular 
proteins involved in signal transduction. 
Another type of oncogene related to ovarian carcinogenesis is a group of 
proteins named G proteins. G proteins have intrinsic guanosine triphosphatase 
(GTPase) activity that catalyzes the exchange of guanosine triphosphate (GTP) 
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for guanosine diphosphate (GDP). Li their active GTP-bound form, G proteins 
are capable of activating other molecules which are involved in signal 
transduction (Berchuck and Bast, 1993). Several different G proteins are 
activated in human cancers because of point mutations. The most ubiquitous 
of these are the ras family which includes Harvey (H-ras), Kirsten (Ki-ras) and 
neuroblastoma (N-ras) genes (Berchuck and Bast, 1993). Ras gene may be 
activated constitutively by point mutation (particular of amino acids 12, 13, 59 
and 61)，amplification or over-expression and such genetic alterations inhibit 
hydrolysis of bound GTP which traps ras in its active GTP-bound state. 
Mutations in ras genes have been noted in many human malignancies. The 
most common ras gene alterations in ovarian tumor involves Ki-ras . Mutation 
in the Ki-ras gene has been observed in malignant ovarian tumors, with 
relatively high frequency seen in borderline tumors (63% of mucinous, 36% of 
serous) (Mok et al., 1993; Teneriello et al., 1993) and mucinous ovarian 
cancers (Enomoto et al.，1990). The fact that Ki-ras mutations are commonly 
detected in borderline ovarian tumors suggests that Ki-ras mutation may 
represent an early genetic alteration involved in the ovarian epithelial cells 
tumorigenesis. On the other hand, the strong association between Ki-ras 
mutation and mucinous epithelial tumors may imply its role in maintaining the 
mucinous differentiation pathways of ovarian epithelial cells (Mok et al., 
1993). This hypothesis is supported by the fact that Ki-ras mutation is also 
frequently seen in other well differentiated mucinous tumors e.g. colorectal 
tumors (Laurent-Puig et al., 1991). 
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The third type of oncogenes transcribed the nuclear transcription factors. 
Their products, when subjected to induction by peptide growth factors, bind to 
specific DNA-regulatory elements and result in transcription of genes involved 
in DNA synthesis and division of normal cells (reviewed by Berchuck and 
Bast, 1993). However, these transcription factors can act as oncogenes when 
they are inappropriately over-expressed. Among the nuclear transcription 
factors, oncogenic activation has been observed most often in the myc 
oncogene family. C-myc gene may be activated by rearrangement or 
amplification. Over-expression of c-myc protein (p62) may also occur. It has 
been reported that serous papillary ovarian carcinoma expressed significantly 
higher p62 c-myc levels compared with normal ovary, while borderline tumors 
showed an intermediate level of expression in between that of normal ovary 
and ovarian carcinoma (Waston et al., 1987). 
Tumor suppressor genes 
Tumor suppressor genes, similar to oncogenes, are involved in the 
regulation of cellular growth and differentiation. However, tumor suppressor 
genes encode proteins that restrain proliferation. They are also termed 
recessive genes because it is only when both alleles of the gene are lost or 
inactivated, the normal constraint to cell proliferation is removed, leading to 
cell immortalization. Loss or inactivation of a tumor suppressor gene can be 
due to point mutation, deletion, mitotic recombination, chromosomal loss, etc. 
(Katso et al., 1997). 
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BRCA1 gene has recently been identified to be important in 
carcinogenesis. Miki et al. (1994) had mapped the BRCA1 gene which is 
located in chromosome 17q 12-21. It is composed of 22 coding exons 
distributed over more than 100 kb of genomic DNA and encodes a protein of 
1863 amino acids (7.8kb mRNA). It is expressed ubiquitously and abundantly 
in breast and ovary. The amino terminal region of this protein contains a zinc-
finger domain which is a motif found in many nucleic acid-binding proteins, 
suggesting that BRCA1 may regulate gene expression, DNA repair, or site-
specific recombination (Ford and Easton, 1995). On the other hand it has also 
a granin motif in the C-terminal domain which suggests that BRCA1 may be 
involved in the regulated secretory pathway (Steeg, 1996; Jensen et al., 1996). 
Li addition, the developmental pattem ofBRCAl expression suggests that it is 
involved in the process of proliferation and differentiation in multiple tissues 
notably in the mammary gland in response to ovarian hormones (Hakem et al., 
1996). More recently, it has been shown that it acts as transcriptional activator 
(Bradley and Sharan, 1996; Chapman and Verma, 1996). The expression of 
BRCA1 gene in ovarian and breast cancer cell lines abrogates the transformed 
phenotype and reduces tumor formation in nude mice, providing proof that it is 
a tumor suppressor gene (Rao et al., 1996; Shao et aL, 1996). Smith et al. 
(1992) reported that loss of heterozygosity on 17q in breast and ovarian tumors 
invariably involves the wild-type chromosome supported the hypothesis that 
cancers in BRCAl-linked families result from the inheritance of an inactivated 
mutation in one copy of the gene followed by a somatic loss of the wild type 
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gene on the other chromosome. It should be noted that all ovarian cancers due 
to BRCA1 inactivation appear to be malignant epithelial tumors, whereas no 
evidence was found to show the association ofBRCAl with borderline tumors 
or benign cysts, and BRCAl-linked ovarian cancers are more likely to be 
serous than mucinous (Narod, 1994). 
The nuclear phosphoprotein p53 has become the subject of intense 
investigation for its tumor suppressing characteristics, p53 has the following 
features: it is the most commonly altered gene yet discovered in human 
malignancy (Hollstein et al., 1991); it suppresses the growth of tumor cells that 
harbor multiple genetic changes (Baker et al., 1990a); germ line mutation of 
p53 has been linked to an inherited predisposition to cancer (Li-Fraumeni 
syndrome) (Malkin et al., 1990); the p53 null mice develop normally but are 
predisposed to tumorigenesis (Donehower et al., 1992); increased amounts of 
cellular p53 protein after DNA damage have been associated with cell-cycle 
arrest (Kastan et al., 1991) and apoptosis (Shaw et al., 1991); and mutations or 
deletions of p53 have been associated with gene amplification (Livingstone et 
al., 1992; Yin et al., 1992) and polyploidy (Cross et aL, 1995). Most of the 
functions of p53 are mediated through several biochemical pathways involving 
transcriptional activation, transcriptional suppression, and inhibition of DNA 
replication (Velculescu and El-Deiry, 1996). 
The p53 gene is located on the short arm of chromosome 17 (Miller et aL, 
1986). It was first discovered in 1979 by virtue of its association with simian 
virus 40 (SV40) large T-antigen and by its apparently high expression in 
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chemically induced tumors or spontaneous transformed cells (Linzer and 
Levine, 1979; DeLeo et al., 1979). Ability to immortalize cells (Jenkins et al., 
1984) and cooperation with ras in transforming cells also led many researchers 
to believe that p53 was a transforming oncogene necessary for cellular 
proliferation. 
The p53 gene did not raise the interest of researchers until 1989 that 
Finlay et al. (1989) discovered the tumor suppressing activity of p53. For 
example, only mutant p53 could cooperate with ras in cellular transformation 
(Hinds et al., 1989)，and wild-type p53 could inhibit transformation induced by 
either adenoviral ElA plus ras or mutant p53 plus ras (Finlay et al., 1989). 
Transfection of a mutant p53 gene into growth-arrested mouse Swiss 3T3 cells 
abrogated the requirement of these cells for platelet derived growth factor 
(PDGF) for the induction of cellular DNA synthesis (Kaczmarek et al., 1986). 
Moreover, colorectal carcinomas that lost one chromosome 17p allele were 
demonstrated to harbor mutations of the remaining allele within the coding 
region of the p53 gene (Baker et al., 1989). By introducing wild-type p53 
gene, the growth of human colorectal carcinoma cells was suppressed (Baker 
et al., 1990a). The protein product of p53 gene normally acts to restrain 
proliferation of cells by binding to specific regions of DNA where it may 
regulate the expression of other genes (Levine et al., 1991; Finlay et al., 1989). 
Some of the target genes which are transcriptionally activated by p53 are bax 
(inducer of apoptosis), FAS/Apol (inducer of apoptosis), MDM2 (feedback 
inhibition regulator of p53), p2iWAFi/cffi ^^^n cycle regulator), whereas the 
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target genes that are repressed by p53 are bcl-2 (inhibitor of apoptosis), PCNA 
(DNA polymerase processivity factor), c-myc (cellular oncoprotein), c-fos 
(cellular oncogene and early response transcription factor) etc. The p53 is 
believed to suppress the development of malignant clones by preventing 
replication of cells that carry genetic damages (Kuerbitz et al., 1992; Yin et al., 
1992). The protective role of p53 in preventing malignancies may have at 
least two facets. On one hand, p53 elicits protective responses by arresting 
cell cycle so as to allow cells to have more time for DNA repair (Smith and 
Fomace, 1996). Recent evidence suggests that p53 may even actively 
participate in DNA repair (Smith et al., 1995; Tolbert and Kantor, 1996). On 
the other hand, p53 may also trigger the programmed cell death (Smith and 
Fomace, 1996) which will be discussed in chapter 4. However, loss of 
functional p53 from the cell has been shown to facilitate malignant 
transformation in experimental models (Finlay et al., 1989; Donehower et al., 
1992). Genetic alterations of p53 in human tumors include allelic losses, 
missense and frameshift mutations, intragenic deletions and epigenetic 
changes (Velculescu and El-Deiry, 1996). Loss of p53 most often occurs as a 
result of mutation of one allele of p53 gene, resulting in an inactive protein 
product that no longer binds to DNA (Levine et al., 1991). It may be due to 
the fact that the mutant p53 protein complexes with and inactivates the normal 
p53 protein (Finlay et al., 1988). Li addition, in cancers in which one allele of 
the p53 gene has undergone mutation, the other allele is frequently absent 
because of partial or complete loss of the short arm of chromosome 17 (Levine 
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et al., 1991). Therefore inactivation of one allele of p53 by point mutation, 
followed by the chromosomal deletion of the other allele account for the loss 
of functional p53 (Baker et al., 1990b). The mutations cluster in four 
evolutionarily conserved hotspot domains, which direct the sequence-specific 
(a 10-bp motif: 5'-PuPuPuC(AnO(iVT)GPyPyPy-3') DNA-binding function 
of the wild-type p53 protein (El-Deiry et al., 1992; Cho et al., 1994; 
Arrowsmith and Morin, 1996). p53 normally exists as a tetramer, and cross-
oligomerization of mutant with wild-type p53 is believed to be the origin of 
the phenotype of mutant p53 (Milner and Medcalf, 1991; Bargonetti et al., 
1992). Most mutant p53 proteins have a prolonged half-life because they are 
resistant to degradation compared to the cells with wild-type p53 proteins 
(Finlay et al., 1988). Thus p53 mutations always lead to over-expression due 
to the accumulation of mutant p53 protein in the nucleus (Kems et al., 1992). 
p53 gene point mutation is frequently found in various types of human 
malignancy such as colorectal (Rodrigues et al., 1990), lung (Iggo et al., 1990)， 
breast (Davidoff et al., 1991)，prostate (Suzuki et al., 1996)，renal pelvis and 
ureter (Furihata et al., 1996) and endometrial cancers (Kohler et al.，1992). A 
recent compilation and analysis of data from 2567 cancers worldwide revealed 
that 37% contained mutations in the p53 gene (Greenblatt et al., 1994), 
including lung and colon (>50%)，esophageal (45%), ovarian (44%), 
pancreatic (44%), skin (44%), stomach (41%), head and neck (37%), bladder 
(34%), sarcoma (31%), prostate (30%), hepatocellular (29%), brain (25%), 
adrenal (23%), breast (22%), endometrial (22%), mesotheliomal (22%), renal 
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(19%), thyroid (13%), hematological (12%), carcinoid (11%), melanoma (9%), 
parathyroid (8%), and cervical cancers (7%). Mutation of p53 gene has been 
detected in epithelial ovarian neoplasms (Marks et al., 1991; Naito et al., 1992) 
whereas abnormalities of p53 have not yet been demonstrated in benign and 
borderline ovarian tumors (Kupryjanczyk et aL, 1994, 1995). 
1.6 Project aims and design 
To sum up, ovarian cancer is still the leading cause of death among all 
gynecologic malignancies (Tortolero-Luna and Mitchell, 1995). Unfortunately, 
the etiology of ovarian carcinogenesis remains unknown. However, genetic 
alterations important in the development of ovarian cancer have been recently 
identified e.g., p53 mutation and over-expression (McManus et al., 1996; 
Diebold et al., 1996;)，over-expression and amplification of HER-2/n^w 
oncogene (Medl et al., 1995; Auranen et al., 1997)，K-ras mutation (Mok et al.， 
1993; Cuatrecasas et al., 1997)，down-regulation of SPARC (Mok et al., 
1996), BRCA1 mutation (Stratton et al.，1997)，etc. Previous publications 
indicated that the carcinogenesis of human ovarian cancers results from 
multiple-step genetic alterations involving a vast number of genes that 
regulated different steps and different pathways during the development of 
malignancies. Identifying such genetic alterations and investigating the 
underlying mechanisms may help understanding the etiology of ovarian 
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carcinogenesis and thus improving the molecular approaches for diagnosis and 
treatment of ovarian tumors. Recently a novel gene, DOC-2, which was 
identified and cloned by Mok et al. (1994). The RNA expression of DOC-2 
gene was shown to be present in normal human ovarian surface epithelium but 
significantly down-regulated or totally absent in all of the fresh ovarian 
carcinomas and human ovarian carcinoma cell lines examined. This finding 
suggested that DOC-2 may be a potential candidate for tumor suppressor gene 
in suppressing ovarian carcinogenesis. Li this report, therefore, an 
immunohistochemical method was used to examine the expression of DOC-2 
protein in normal ovaries and various ovarian tumors (benign, borderline and 
invasive ovarian tumors) to see if the protein expression can corroborate the 
differential expression of DOC-2 mRNA in human ovarian cancer discovered 
by Mok et aL (1994). On the other hand, DOC-2 cDNA clones had been 
transfected into human ovarian carcinoma cell line SKOV3. Therefore in the 
second part of this report, the comparison of the growth characteristics of the 
DOC-2 transfected carcinoma cell lines and cell lines transfected with the 
transfection vector only were made in both in vivo and in vitro system. Li 
addition, previous publications had found that DOC-2 gene shared a highly 
conserved domain with some genes that are actively involved in embryonic 
development. Thus in the third part of this report, focus was given on whether 
this novel gene has any function on embryonic development, apart from its 
possible tumor suppressing activities, tnmunohistochemical method was 
employed to study the expression pattem of DOC-2 protein in mouse embryos. 
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Other than the DOC-2 gene, there are a lot of genes which have been 
suggested to have their expression patterns altered during carcinogenesis. For 
instance, many genes regulating apoptosis, a highly gene-regulated cell death 
programme, have been suggested to involve in various human malignancies. 
However, little is known about the roles of those apoptosis regulatory genes in 
ovarian carcinogenesis. Li the last part of this report, in situ TUNEL labelling 
method was firstly used to study the occurrence of apoptosis during ovarian 
carcinogenesis. Furthermore, expression patterns of two well documented 
apoptosis-related gene were examined to see if changes in expression pattern 
of these genes were related to the development of ovarian epithelial tumors via 
apoptosis. 
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Chapter 2 DOC-2, a differentially expressed gene in human 
ovarian cancer 
2.1 Introduction 
As mentioned in the previous chapter, multiple genetic alterations 
involving the activation of oncogenes and/or the inactivation of tumor 
suppressor genes occur during transformation of normal ovarian surface 
epithelial cells to malignant tumors. Thus, comparison of gene expression 
patterns between normal and tumor cells is extremely important in identifying 
differentially expressed genes involved during ovarian carcinogenesis. 
Current methods to distinguish differentially expressed mRNAs in 
comparative studies rely largely on subtractive hybridization or differential 
hybridization techniques in which two RNAs can be compared at one time. 
Most recently, RNA differential displays (Wong et al., 1993) have been 
employed to identify genes differentially expressed in malignancies. Wong et 
aL (1993) and Mok et al (1994) had successfully identified and cloned 
differentially expressed genes in human epithelial ovarian cancer. DOC-2 
(Differentially expressed gene in Ovarian Cancer) is one of the newly 
identified genes in ovarian cancer. 
DOC-2 was originally identified as a 767-bp cDNA fragment which 
has one open reading frame suggesting that the gene may be translated (Mok et 
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al., 1994). Albertsen et al. (1996) had determined the complete 3.2 kb cDNA 
sequence of DOC-2. DOC-2 gene is localized in chromosome 5pl3 (by the 
technique of fIuoresence in situ hybridization). The predicted translational 
product of DOC-2 cDNA was a hydrophobic protein of 770 amino acid 
residues with a molecular weight of 82.5 kDa. Albertsen et al. (1996) also 
determined that DOC-2 is expressed in a tissue-independent manner in at least 
seven different human tissues, including ovarian surface epithelium, small 
intestine, arm skin, fallopian tube, prostate cancer cell lines, brain stem and 
fetal retina. Li addition, DOC-2 gene was shown to have an alternative splice 
form in which a 60-bp exon between bases 729 and 789 in the cDNA sequence 
is absent. The DOC-2 cDNA fragment is present in normal human surface 
epithelial cells and culture of the normal human ovarian surface epithelial cells 
(HOSE), but consistently absent or down-regulated in all of the fresh ovarian 
cancer tissues and the ovarian cancer cell lines from the differential display. 
The differential expression of the gene was also confirmed by Northern 
analysis in which signals for DOC-2 mRNA was observed only in the normal 
ovarian epithelial cells and HOSE cell culture. In situ hybridization using both 
sense and antisense riboprobe showed that hybridization signals were 
restricted to the normal human ovarian surface epithelium (Mok et al., 1994). 
However, the potential functional roles of this gene is still not fully 
understood. 
Although down-regulation of DOC-2 RNA expression in ovarian tumors 
as compared with normal ovarian epithelial cells has been detected by in situ 
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hybridization and Northern analysis, the expression of the DOC-2 protein 
expression and different types of ovarian cancer has not been established. Li 
this chapter, an anti-DOC-2 antibody was employed to study the DOC-2 
protein expression pattem in normal ovaries and various types of ovarian 
epithelial tumors including benign, borderline and malignant (invasive) 
ovarian epithelial tumors. Li addition, a full length of DOC-2 sequence was 
inserted into a pBluescript vector and the vector, together with the DOC-2 
insert, was transfected into an ovarian carcinoma cell line (SKOV3) to study 
whether DOC-2 gene itself has the potential function of inhibiting growth of 
ovarian carcinoma cells in the in vitro culture and in nude mice. 
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2.2 Materials and Methods 
2.2.1 Expression of DOC-2 in human ovarian tissues 
2.2.1.1 Preparation of specimen 
A total of 79 fresh human ovarian tissues, including 13 normal ovaries, 6 
benign ovarian tumors, 16 borderline ovarian tumors and 44 invasive epithelial 
ovarian tumors used in this study were obtained from the Brigham and 
Women ‘ s Hospital, Harvard Medical School. Patient ‘ s consent was obtained 
prior to the collection of surgical materials. The tissues collected were fixed in 
10% buffered formalin and embedded in paraffin blocks. The 
histopathological diagnosis was confirmed by two gynecological pathologists 
(Dr WR Welch and Dr DA Bell at the Brigham and Women ‘ s Hospital) after 
examining the ovarian tissues sections stained with hematoxylin and eosin. 
The tumors were classified and graded according to the Litemational 
Federation of Gynecology and Obstetrics (FIGO) criteria for ovarian tumors 
(Table 1). Among those invasive tumors, 20 cases were grade 1 carcinoma; 8 
cases were grade 2 and 16 cases were grade 3 based on the FIGO staging 
system. 
2.2.1.2 Immunohistochemical studies of the expression of DOC-2 protein in 
human ovarian tissues 
DOC-2 protein expression was detected by the Avidin-Biotin peroxidase 
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Complex (ABC) method. However, antibody specifically used for targeting 
human DOC-2 protein has not yet commercially available. Therefore we used 
another antibody, aM2, which was a generous gift from Professor Charles 0 . 
Rock at the Department of Biochemistry, St. Jude Children's Research 
Hospital, Tennessee. aM2 was used to detect DOC-2 protein expression. The 
aM2 antisera was raised against a synthetic peptide 
(roEKTGVffiHEHPVNKIS) corresponding to amino acid residues 105-122 of 
p96 protein, p96 protein was a murine mitogen-responsive phosphoprotein 
first discovered to be present in a murine macrophage cell line BAC1.2F5 (Xu 
et al., 1995). p96 showed a 81% amino acid identity with the predicted DOC-
2 hydrophobic protein (Albertsen et al., 1996) and was well accepted to be the 
murine homolog of DOC-2. Furthermore, the sequence of the synthetic 
peptide used for synthesizing the aM2 antisera was unique to that found in 
human DOC-2. Therefore aM2 antisera was used as primary antibody in this 
study to detect the expression of DOC-2 protein in human ovarian tissues. 
L:nmunohistochemistry was performed with the ABC Vectastain kit (Vector 
Laboratories, Burlingame, CA, USA) according to the supplier ‘ s protocol. 
Human ovarian tissues were serially sectioned into 7^im and mount on a 
cleaned TESPA (3-aminopropyltriethoxysilane, Sigma, St Louis, MO, USA)-
coated slides. The sections were allowed to incubate in a 60°C oven for about 
half an hour. They were then deparaffinized in xylene and hydrated to PBS 
(phosphate buffered saline) through graded ethanol (absolute ethanol ~> 95% 
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^ 80% "> 75% — PBS). After washing in PBS (Appendix I) thrice, the 
sections were incubated in normal horse serum (ABC Vectastain kit, 3 drops 
in 10ml PBS) for at least 45 minutes at room temperature to minimize the 
background staining generated from non-specific binding. After blocking with 
normal horse serum, the excess serum was drained away and the sections were 
incubated with primary antibody ovemight at 4°C. The aM2 antisera used to 
detect the expression of DOC-2 was at a dilution of 1: 4000 in l%BSA-PBS. 
1% BSA in PBS was used instead of the primary antibody in the negative 
control. Li order to further confirm the specificity of the polyclonal antibody, 
aM2 antisera was preadsorbed ovemight at 4°C with the synthetic peptide in 
which its sequence was unique to the expected gene product of DOC-2 
(60mg/ml, Genosys, USA). The preadsorbed antibody was then used as a 
preadsorbed negative control to replace the primary antibody. The sections 
were washed in PBS throughout and subsequently secondary antibody which 
were specifically bound to the rabbit antibody added previously. The 
secondary antibody, that is, the biotinylated anti-rabbit antibody (1:200, 
diluted with 1 %BSA-PBS) was applied to the sections and incubated for 30 
minutes at room temperature. After incubation, excess secondary antibody 
which was not yet bound to the sections were washed away with PBS. For the 
ABC immunohistochemical method using peroxidase as enzyme, endogenous 
peroxidase that was present in the sections was inhibited by the addition of 
0.01% H2O2 in methanol for 15 minutes. The H2O2 was then washed away by 
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PBS. Amplification of immunostaining signal was achieved by the addition of 
ABC (Avidin-Biotin peroxidase Complex) reagents in a dilution of 1:1:100 
(Reagent A: Reagent B: PBS). ABC reagent is a complex of the avidin 
(glycoprotein) and biotin (linked up with peroxidase) that binds to the biotin 
molecule of the secondary antibody. The ABC reagent was then applied to the 
section and incubated for 30 minutes and washed with PBS. Afterwards, the 
sections were washed with Tris buffer (0.05M, pH 7.2, Appendix E) and 
subsequently color reaction was carried out by incubating the sections for 5 
minutes in peroxidase substrate solution (0.05% DAB: 3,3 ‘ -diaminobenzidine 
tetrahydrochloride, in 30ml Tris Buffer with 6^1 of 30% H2O2 as catalyst). 
Finally, the sections were counterstained with hematoxylin, dehydrated 
through graded ethanol and mounted using Permount. 
2.2.1.3 Quantitation of immunoreactivity 
The immunohistochemically stained sections were examined by two 
independent observers ( Mr. K.K. Cheung, at Department of Anatomy, 
Chinese University of Hong Kong and Dr. S.C. Mok at Gynecologic Oncology 
Lab., Harvard Medical School, USA). Five to seven sections were taken from 
each specimens for scoring. Results of immunoreactivity was quantified on a 
12-point weighted score (intensity score x percentage score) representing both 
the intensity (Litensity score: 1 for weak, 2 for medium, 3 for strong) and the 
percentage (Percentage score: 1 for 5-25%, 2 for 25-50%, 3 for 50-75%, 4 for 
over 75% of positive cells) of immunopositive cells. 
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2.2.2 Effect of DOC-2 transfection on growth rate of the ovarian cancer 
cell line SKOV3. 
2.2.2.1 Cell line 
Ovarian carcinoma cell line SKOV3 was purchased from ATCC 
(Rockville, MD, USA). SKOV3 was cultured in Medium 199 and MCDB 105 
( 1 : 1，V:V ) (Appendix DI and FV, respectively) supplemented with 10% fetal 
bovine serum, 100 units/ml penicillin and 100|Lig/ml streptomycin. 
2.2.2.2 Transfection of DOC-2 to SKOV3 ovarian carcinoma cell line 
The procedure for transfection was identical to that described by Mok et 
al. (1996). A full length DOC-2 cDNA (3.2 kb) was released from BamHI and 
XhoI cloning site from the pBluescript>T^ambda ZapH vector (Stratagene, La 
Jolla, CA, USA) and inserted into the pCDNA3 neo eukaryotic expression 
vector (Litrogen, La Jolla, CA, USA) in the sense orientation. The construct 
was then transfected into the recipient cells SKOV3 by calcium phosphate 
precipitation method. This gave rise to the SKDOC-2 transfected cell clone. 
On the other hand, the vector pCDNA3 neo alone without the insert was also 
transfected into SKOV3 using the same method as described above and the 
resulting transfected cell clones carrying only the vector only was SKNEO cell 
clones. For the DOC-2 insert transfection, 3 clones were successfully inserted 
and transfected, and the cell lines established were named SKDOC-2-8, 
SKDOC2-36 and SKDOC-2-43. Two neo cell lines, namely SKNEO-1 and 
SKNEO-2, which were transfected with pCDNA3 neo vector alone, were also 
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established. All the transfected cell lines were subjected to G418 (500^g/ml, 
BRL, Gaithersburg, MD, USA) selection. Restricted clones representing the 
stable transfected cells were ring-cloned and expanded (Mok et aL, 1996). The 
expression of DOC-2 RNA and its translated protein of the stable transfected 
cells were examined by RT-PCR and Westem blot analysis. Figure 1 showed 
the expression levels of DOC-2 in SKOV3 and all the transfected cell lines. 
Both RT-PCR and Westem analysis showed high levels of DOC-2 expression 
in the SKDOC-2-43. Whereas densitometer indicated that SKDOC-2-36 cell 
line showed somehow a 3 to 4 fold lower DOC-2 expression level compared to 
SKDOC-2-43. SKDOC-2-8 showed a much lower expression level. The 
parental SKOV3 cell line and the neo transfected SKNEO-1 and SKNEO-2 
cell lines did not show DOC-2 expression. All the transfected cell lines were 
then cultured in Medium 199 and MCDB 105 ( 1 : 1 ) supplemented with 10% 
fetal bovine serum, Geneticin (500|0,g/ml) and 100 units/ml penicillin and 
lOO^g/ml streptomycin. All the transfections of SKOV3 cell lines (SKDOC-
2-8, SKDOC-2-36, SKDOC-2-43, SKNEO-1 and SKNEO-2) were done by 
Dr. S. C. Mok at Brigham and Women's Hospital, Harvard Medical School, 
Boston, U.S.A. 
2.2.2.3 Growth curve of the transfected ovarian carcinoma cell lines 
When the transfected cell lines reached 80% confIuency, the medium was 
then withdrawn and discarded. The cells were washed with 8ml Hank Buffer 
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Salt Saline (HBSS, appendix V) to remove the serum so as to allow 
subsequent trypsinization. After washing with HBSS, the cells were then 
trypsinized with 3ml (0.25%) trypsin (Sigma, MO, USA) inside a 5% CO2 
incubator at 37°C. The time required for trypsinization was 3 minutes for 
SKNEO-1 and SKNEO-2, 4 minutes for SKDOC-2-36 and SKDOC-2-43, and 
10 minutes for SKDOC-2-8 cell line. The trypsinized cells were transferred 
into a centrifuged tube and were centrifuged at 1500rpm for 5 minutes. The 
supernatant was discarded and the packed cells were resuspended in the 
culture medium. The number of cells was counted by a haemocytometer under 
a phase-contrast microscope (Nikon, Japan). For constructing a standard curve 
to calculate the cell density in each well from the absorbance, a total of nine 2-
fold serial dilutions were made with the highest starting concentration of 6.4 x 
10^ cells/lOOjxl/wdl. The cells were then added to the 96-well culture plate 
(Coming, NY, USA). The 96-well culture plates were then retumed to the 5% 
CO2 incubator at 37°C. The culture used for constructing a standard 
absorbance curve was harvested after the cells attached completely onto the 
culture well surface (it took about 2-4 hours). For constructing a growth 
curve, 1 X 10^  cells/lOO^il/well were selected and the cells were seeded onto 
96-well culture plates. The cultures were harvested after 2-4 hours (0 day), 48 
hours (2 days), 96 hours (4 days), 144 hours (6 days) and 192 hours (8 day) 
incubation. After 4-day culturing, 50p,l of cultured medium inside the 6-day 
and 8-day culture plates were replaced by fresh medium by discarding 50p,l old 
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medium and adding 50p,l new culture medium. The cultures were then put 
back to 5% CO2 incubator at 37°C. When harvested, cells were first examined 
under a phase-contrast microscope (Nikon) and were then harvested by 
discarding the medium from each well. lOOp.1 of 1% crystal violet (in 20% 
methanol) was added and the culture plate was then put back in the incubator 
for 8 minutes. Afterwards, the crystal violet was discarded and each well was 
rinsed thoroughly with several changes of PBS. The plate was then dried 
ovemight. 50^1 lysis buffer (1% acetic acid in 50% alcohol) was added in 
each well and the absorbance was recorded at 595nm using the microplate 
reader ( Bio-Rad，CA, USA). 
2.2.3 In vivo tumorigenicity study 
To test the hypothesis that endogenous DOC-2 can suppress tumor 
growth in vivo, human ovarian carcinoma cell lines and DOC-2 transfected 
cell lines were inoculated into nude mice to observe the xenograft formation. 
SKNEO-2 cell line which carried the vector only and, SKDOC-2-43 cell line 
which showed the highest DOC-2 expression, were tested. 1 x 10^  
exponentially growing cells were inoculated behind the anterior forelimb of 4-
week-old athymic mice (athymic nu/nu). Each mouse was inoculated on both 
sides of the anterior forelimb. Each group consisted of 4 mice and were 
maintained in a pathogen-free facility for 4 weeks. Growth curves for 
— 
Chapter 2 Materials and Methods 
xenografts were determined by extemally measuring tumors in two dimensions 
using a caliper. Volume (V) was determined by the following equation as 
described (Sun et al.,1994), where L is the length and W is the width of the 
xenograft: V = (L x W^) x 0.5. 
Besides, the microscopic appearances of the SKOV3 transfectants 
(SKNEO-1, SKNEO-2, SKDOC-2-36 and SKDOC-2-43) were recorded by 
taking photographs under phase contrast microscope when the cell lines 
reached 80% confluency. At 80% confluency, the SKOV3 parental ovarian 
carcinoma cell line was shown to grow in log-phase. 
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2.3 Results 
2.3.1 Expression of DOC-2 in human ovarian tissues 
To study the expression of DOC-2 in normal and cancerous ovarian 
tissues, 79 paraffin-embedded tissues were sectioned and stained for 
immunoreactivity using aM2 polyclonal antibody raised from rabbit which 
specifically binds to a unique sequence of DOC-2 gene product. The 
immunohistochemistry based on the avidin-biotin complex (ABC) method was 
employed for this studies. Negative control in which the primary antibody 
aM2 was replaced by 1% BSA in PBS was performed. Li addition, the 
synthetic peptide used to raise the aM2 antibody was also used in 
preadsorption control by incubating the primary antibody aM2 with the 
synthetic peptide. The preadsoption control is important in demonstrating the 
specificity of the polyclonal antibody acting against the DOC-2 protein. A 12-
point weighted score taken into account both the signal intensity and 
percentage of immunopositive cells was used to quantify the immunoreactivity 
of DOC-2 protein. Brown reaction products were found to localize in the 
cytoplasm of the surface squamous epithelial cells in normal ovaries (Fig. 2A), 
indicating the presence of DOC-2 protein in the cytoplasm. All benign 
specimens showed dark brown positive staining in the cytoplasm of the surface 
cuboidal epithelial cells (Fig. 2B). The staining intensity in the borderline 
tumors (Fig. 2C) was similar to those found in normal ovaries, but the cells 
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appeared cuboidal and columnar in shape. However, invasive tumors of grade 
I serous subtype showed relatively weak immunoreactivity (Fig. 3A) compared 
with that of normal ovaries, benign and borderline ovarian tumors. DOC-2 
immunoreactivity was totally absent in grade EI invasive tumors (Fig. 3B). Jn 
the negative control (borderline tumor) where the primary antibody was 
replaced by 1% BSA in PBS, both the epithelium and stroma did not show any 
positive staining (Fig. 3C). DOC-2 protein was expressed in surface 
epithelium of all but one of normal ovaries (12/13, 92%), all of the benign 
tumors (6/6，100%) and most of the borderline ovarian tumors (12/16, 75%), 
but only 23% (10/44) of invasive (malignant) ovarian tumors (Table 2). Graph 
1 summarized the distribution of DOC-2 protein weighted scores among 
different ovarian tissues. The graph indicated that expression of DOC-2 
protein was frequently observed in normal ovaries, benign and borderline 
tumors, but appeared to be rare in invasive tumors especially in high grade 
tumors (grade E and HI). 
Among all the invasive epithelial ovarian tumors studied, DOC-2 protein 
was expressed in 40% (8/20) of grade I tumors and 25% (2/8) of grade H 
tumors. None of the grade HI invasive tumors (0/16) demonstrated DOC-2 
immunopositivity (Table 2). kiterestingly, for all the invasive tumors showing 
DOC-2 expression, 5 out of 8 (62.5%) grade I tumors and all (2/2，100%) the 
grade E tumors were of mucinous histologic subtypes. The epithelial cells of 
invasive mucinous tumors were tall columnar, with mucin-secreting cells 
frequently found. Staining was appeared light brown in the cytoplasm of the 
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epithelium in grade I (Fig. 4A) and grade H (Fig. 4B) mucinous tumors. Both 
the intensity and proportion of DOC-2 immunopositively cells in mucinous 
tumors was higher than those of serous tumors of the same histological grade 
(Fig. 3A-B). Excluding all the mucinous invasive tumors, only 3 of 15 (20%) 
grade I tumors had DOC-2 expression (Table 3)，with relatively lower 
weighted score (0-3.4) shown in Graph 2. DOC-2 expression was, however, 
totally absent in all of the remaining grade E tumors (Table 3)，among which 
5 were serous and 1 was endometrioid tumors. All the negative grade HI 
tumors were of serous subtypes except one which was endometrioid tumors. 
On the other hand, the preadsorption control using grade I mucinous invasive 
tumors also revealed no positive staining at all in the tumor sections (Fig. 4C). 
2.3.2 Effects of DOC-2 transfected gene on the growth rate of the human 
ovarian cancer cell line SKOV3 
2.3.2.1 Standard curves for calculating cell density from absorbance 
The absorbance at 595nm was measured at different cell densities of 
DOC-2- transfected SKOV3 cell lines after the cells were stained up by crystal 
violet. Standard curves for each cell lines at different cell densities were 
plotted against absorbance. The standard curves for each cell lines were used 
as reference for assessing the growth curves of different cell lines. A 8-day 
growth kinetic study of the neo transfectants (SKNEO-1 and SKNEO-2) and 
DOC-2 transfectants (SKDOC-2-8, SKDOC-2-36 and SKDOC-2-43) was 
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performed to demonstrate the effects of DOC-2 expression on the growth rate 
of the SKOV3 ovarian carcinoma cell line. 
2.3.2.2 The effect of DOC-2-transfection on the growth rate of the human 
ovarian cancer cell line SKOV3 
Growth curves of two neo transfectants (SKNEO-1 and SKNEO-2) and 
three DOC-2 transfectants (SKDOC-2-8, SKDOC-2-36 and SKDOC-2-43) 
(Graph 3) were generated to determine whether DOC-2 expression led to 
alteration of growth parameters in human ovarian cancer cell lines. On day 8， 
the cell density of the neo transfectants was about 2.5 to 3 fold higher than 
DOC-2 transfectant SKDOC-2-43, which has been shown to have the highest 
DOC-2 expression. SKDOC-2-43 cell line showed the lowest growth rate 
(reflected by the slope) among all the cell lines studied (Graph 3). The growth 
of SKDOC-2-43 showed a slight decrease after 8 days，while the neo 
transfectant (SKNEO-2) was still at exponential log phase. Although 
SKNEO-1 showed a slightly decrease in growth rate after 8 days, the cell 
density was much higher than that of SKDOC-2-43 (Graph 3). However, 
SKDOC-2-8 and SKDOC-2-36, which have considerably lower DOC-2 
expression, showed a similar growth rate as the neo transfectants. For 
SKDOC-2-36 having a higher DOC-2 expression than SKDOC-2-8, also 
demonstrated a lower rate of growth along the whole kinetic studies, with an 
obvious difference on day 6 (Graph 3). 
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2.3.3 In vivo tumorigenicity 
Athymic nude mice were employed to establish the in vivo tumorigenic 
capacity of tumor cells with and without the DOC-2 gene. The transfectant 
SKNEO-2, which carried the vector only but without the DOC-2-gene, and the 
transfectant SKDOC-2-43, which showed the highest expression of the DOC-2 
protein (Fig. 1)，were chosen to inoculate into the nude mice and the volumes 
of the tumor formed from the two transfectants in the nude mice were 
measured every week until the fourth week. It was found that SKNEO-2 cell 
line, which did not show any DOC-2 protein expression, induced formation of 
tumor clumps in 7 of 8 (75%) of nude mice inoculated. The SKNEO-2-
induced tumors revealed a continuous increase in the volume of xenografts 
(Graph 4). The growth of xenografts seemed to slow down from week 2 to 
week 3, and then showed an increase in the rate of growth of xenografts 
indicated by a further increase in xenograft size. In contrast, SKDOC-2-43 
which have been previously shown to have the highest DOC-2 expression, was 
not able to induce tumor formation (in 0 of 6 (0%) of nude mice inoculated) 
and the tumor masses as formed in the nude mice regressed and totally 
disappeared by week 4 (Graph 4). 
Examination of microscopic appearance for different SKOV3 transfected 
cell lines under phase contrast microscope indicated that there was an obvious 
difference in morphological appearance between SKDOC-2-43 and other 
SKOV3 transfectants at about 80% confluency. Generally, the majority of 
cells found in SKNEO-l(Fig. 5A), SKNEO-2 (Fig. 5B) and SKDOC-2-36 
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(Fig. 5C) cell lines were of oval shape. In contrast, most of the cells of 
SKDOC-2-43 cell line appeared flattened and were predominantly polygonal 
in shape (Fig. 5D). 
— 
Chapter 2 Discussion 
2.4 Discussion 
The immunohistochemical staining technique is a rapid and convenient 
method to detect the expression of proteins present in the tissue sections in 
situ. Such technique also provided the spatial patterns of protein expression 
and by using this technique, one can identify the types of cells that express the 
proteins concerned. The immunohistochemical analysis was employed to 
study the expression of the DOC-2 protein in normal human ovarian tissues 
and various types of ovarian epithelial tumors including benign tumors, 
carcinomas of low malignant potential (borderline), and invasive (malignant) 
ovarian tumors. The results of immunohistochemistry showed that the DOC-2 
protein was expressed in normal ovaries (92%). Li contrast, protein 
expression was significantly down-regulated in invasive ovarian tumors 
(23%). Such results were consistent with the findings by Mok et al. (1994). 
They observed that DOC-2 mRNA was expressed in normal human ovarian 
epithelium but significantly down-regulated or totally absent in all the fresh 
ovarian carcinoma tissues and human ovarian carcinoma cell lines examined. 
Li the present study, immunohistochemical examination of the DOC-2 protein 
expression were also performed on benign and borderline ovarian tumors. 
Literestingly, the DOC-2 protein was also expressed in benign (100%) and 
borderline (75%) tumors, which had not been reported previously. Therefore, 
DOC-2 expression was found in normal ovaries, benign and borderline tumors, 
but was down-regulated in invasive ovarian tumors. These findings suggested 
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that down-regulation of DOC-2 may be more important in the development of 
invasive ovarian tumors than that of benign and borderline tumors. Although 
a synthetic polyclonal antibody was used, negative controls using 1 % BSA in 
PBS and preadsorbed antibody (primary antibody previously preasdorbed with 
a unique sequence of DOC-2 protein to substitute the primary antibody) 
revealed no positive immunohistochemical signal, indicating the high 
specificity of the antibody against DOC-2 protein. It was also found that most 
of the invasive tumors expressing DOC-2 protein were of mucinous histologic 
subtypes, and the DOC-2 protein expression was only detected in 8% (3/37) in 
nonmucinous invasive tumors (mainly serous tumors). Li those nonmucinous 
invasive tumors expressing the DOC-2 protein, the weighted score were lower 
than that of the mucinous tumors. Results obtained from Papp et al. (1996) 
had suggested that different genetic changes were responsible for the 
development of different histological subtypes of ovarian cancers. Benign, 
borderline and invasive tumors do not represent a continuum of tumors with 
different degrees of malignancies. On the other hand, mucinous tumors are 
generally believed to be of endocervical Mulierian in nature i.e. the neoplastic 
epithelial cells undergo differentiation along various Mullerian pathway and 
ultimately commit into mucinous forms that resemble endocervical epithelium. 
Whereas some of the mucinous tumors are, however, suggested to be 
monophyletic gastrointestinal teratomas of germ cell origin (Hart, 1981) which 
undergo totally different transformation pathway. Therefore the findings in the 
present study suggested that the presence of DOC-2 protein expression in 
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human ovaries may have the effect of preventing the surface epithelial cells 
from transforming into serous or endometrioid tumors but not the mucinous 
subtypes, and the down-regulation of DOC-2 expression may be important in 
the carcinogenesis of serous and endometrioid invasive ovarian tumors. 
However, the immunohistochemical studied gave no information on how 
DOC-2 suppressed tumor formation. 
Li order to function as a tumor suppressor gene, the corresponding gene 
product should be able to suppress cell proliferation (Marshall, 1991). Li the 
present study, an in vitro cell culture model using gene transfer manipulation 
was used to assess the effect of transfection of DOC-2 gene on the growth rate 
of human ovarian carcinoma cell line SKOV3 which was shown to be DOC-2-
deficient (Mok et al., 1994). Three DOC-2 transfectants (SKDOC-2-8, 
SKDOC-2-36 and SKDOC-2-43) and two neo transfectants (SKNEO-1 and 
SKNEO-2) were used for the study of 8-day cell growth in a 96-well culture 
plate. For all the DOC-2 transfectants, DOC-2 expression was confirmed by 
RT-PCR and Westem blotting. Quantitative analysis of DOC-2 expression in 
the three DOC-2 transfectants using densitometer revealed that DOC-2 protein 
expression in the three cell lines varied, among which SKDOC-2-43 showed 
the highest expression level, while SKDOC-2-36 showed a 3 to 4 fold lower 
expression levels than that of SKDOC-2-43. SKDOC-2-8 showed a much 
lower expression level than SKDOC-2-36 (Fig. 1). DOC-2 protein expression 
was totally absent in the two neo transfected cell lines and acted as negative 
controls for the protein expression. 
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The result for the growth rate analysis was obtained by measuring the 
absorbance of cells at 595nm after the cells were stained with crystal violet. 
Standard curves for individual cell line were constructed as references for 
plotting the growth curve. From the results of the growth curve studies, it was 
found that there was a significant difference in the growth rate. SKDOC-2-43 
showed a slightly decrease in growth rate at day 8 as compared with day 6, 
while the SKNEO-2 still underwent an exponential growth. SKNEO-1 also 
showed a slightly decrease in growth rate at day 8，but the cell numbers were 
much higher than that of SKDOC-2-43. Statistical analysis suggested that 
SKNEO-1 and SKNEO-2 had no significant difference along the whole culture 
period. However, SKDOC-2-43 showed statistically a significant difference (p 
< 0.05) from both SKNEO-1 and SKNEO-2 transfectants. The large 
difference in the growth rate between SKDOC-2-43 and the neo transfectants 
suggested that DOC-2 expression inhibited the growth of SKOV3 ovarian 
carcinoma cell line. However, the results also showed that the other two 
DOC-2 transfectants, SKDOC-2-8 and SKDOC-2-36 which had considerably 
lower DOC-2 expression level compared to SKDOC-2-43, demonstrated cell 
densities similar to those of the two neo transfectants on day 8. The difference 
in growth rate among the SKDOC-2 transfectants may be due to the 
insufficient expression level of DOC-2 protein in SKDOC-2-8 and -36 to exert 
its growth-inhibiting effect. It appeared that the DOC-2 expression level has 
to reach a threshold value before the DOC-2 protein can inhibit the overall 
growth of the SKOV3 cell line. SKDOC-2 36 which has the DOC-2 protein 
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expression higher than SKDOC-2-8 showed a retarded growth rate in day 6 of 
culture when compared with neo transfectants (p < 0.05) and SKDOC-2-8. As 
the cell densities of SKDOC-2-36 increased and the cells became more 
densely packed, cells resumed their capacity to divide rapidly and started to 
proliferate exponentially. However, SKDOC-2-43 which had the high 
expression level of DOC-2 did not show piling up of cells. The growth rate of 
SKDOC-2-43 remained low throughout the study. It seemed to suggest that 
the effects of DOC-2 expression in normal ovaries may also function to 
regulate the early pathway of cell proliferation by inhibiting cell growth which 
was responsible for ovarian carcinogenesis, and an insufficient or low level of 
DOC-2 expression may ultimately fail to block such pathway. However, when 
the DOC-2 protein expression is sufficiently high, the growth of the 
transfectant SKDOC-2-43 was inhibited throughout the 8-day study period. 
It was shown in the present study that the transfected cell line SKDOC-2-
43 which carried the DOC-2 gene and showed a strong expression of DOC-2 
protein grew faster in vitro than the cell lines which did not show expression 
or showed only a weak expression of the DOC-2 protein. The tumor forming 
capacity in vivo was further examined by inoculating the non-expressing 
transfectant SKNEO-2 and the expressing transfectant SKDOC-2-43 into 
homozygous {nu/nu) nude mice. The results obtained for the SKDOC-2-43 
and SKNEO-2 cell lines indicated that there was a significant difference in the 
growth of xenografts in 4 weeks after inoculation (Graph 4). The nude mice 
inoculated with SKNEO-2 showed a higher rate of growth of xenografts and 
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the xenografts appeared to continue to grow even after 4 weeks. Li contrast, 
SKDOC-2-43, with a high DOC-2 protein expression, showed a retarded 
growth in xenografts and regressed afterwards, and finally disappeared. These 
evidence showed that DOC-2 expression can inhibit ovarian tumor growth in 
vitro and in vivo and strongly suggested that inactivation or down-regulation of 
DOC-2 may play a role in the development of ovarian cancer. 
Examinations of microscopic appearance showed that SKDOC-2-43 
transfected cell line was characterized by a predominantly flattened and 
polygonal appearance, compared with other SKOV3 transfectants which were 
generally of oval or elongated shape. Whether the transfection of DOC-2 gene 
into SKOV3 cells leading to an inhibition of cell growth is accompanied by a 
change in cell morphology requires further investigation. 
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Chapter 3 DOC-2 expression in mouse embryonic 
development 
3.1 Introduction 
DOC-2, apart from being a potential candidate for tumor suppressor gene 
for human ovarian epithelial cancer, is also suspected to be involved in 
tyrosine kinase signal transduction pathway. Bork and Margolis (1995) have 
found that several proteins, including the gene product of DOC-2, share a 
homologous domain so called phosphotyrosine interaction domain (PED). FJD 
was firstly found in Shc protein which is involved in signal transduction. Shc 
is an SH2 (^rc Homology 2) domain containing protein that, when subjected to 
activation by various growth factors and cytokines, becomes tyrosine-
phosphorylated and binds to GrB2, coupling Shc to the Ras activation pathway 
(Rozakis-Adcock et al., 1992). Blaikie et al. (1994) have identified the PE) 
region in Shc which appear structurally unrelated to SH2 domain but can bind 
tyrosine-phosphorylated proteins. This region may impart on Shc its unique 
ability to bind to the Asn-Pro-X-Tyr (P) motif found in many tyrosine-
phosphorylated proteins, including growth factor receptors (Obermeier et al., 
1993). The average length of the FJD is about 100 amino acids and is 
suggested to be a globular domain, and the arrangement of the helices and p 
strands indicates the presence of an antiparallel p sheet. Although all the 
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sequences share common features such as hydrophobicity patterns and 
conserved motif, only two positions appear to be invariant (Gly-58 and Ser-
151 ofp52 Shc). 
The expected role in tyrosine kinase signal transduction of PD3 is 
supported by the identification of a PED in the disabled gene, which is a 
tyrosine-phosphorylated protein found in Drosophila (Gertler et al., 1993). 
The Drosophila disabled gene is a second modifier of the abl mutant 
phenotype. Drosophila with both abl and disable defects have an embryonic 
lethal phenotype and fail to form proper axonal connections in the central 
nervous system. The two gene products of abl and disabled genes illustrated 
functional redundancy, that is, the expression of either abl and disabled gene 
restores the embryonic axonal architecture. The gene product of disabled 
gene, the dab protein, is primary localized in central nervous system axon 
bundles but are also present in the peripheral nervous system cell clusters and 
the body wall musculature. 
On the other hand, Xu et al. (1995) also identified a protein termed p96 
that, likewise, harbor a PJD. Alignment of the amino terminal region of p96 
(residues 40-180) and Dab (residues 43-179，i.e. PED) showed that they were 
46% identical and 66% similar in the region. However, p96, unlike dab which 
is tyrosine phosphorylated, phosphorylated exclusively on serine residues 
following stimulation by mitogen (i.e. colony-stimulating factor 1，CSF-1) in a 
murine macrophage cell line. CSF-1 is a growth factor that is extremely 
important for the differentiation, proliferation, and survival of cells of the 
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monocytic lineage (Stanley, 1985). Autophosphorylation of the CSF-1 
receptor promotes its interaction with cytoplasmic proteins that activate 
multiple signal transduction pathway and culminate in a wave of immediate 
early gene expression (Sherr, 1991; Vairo and Hamiliton, 1991). In addition, 
CSF-1 is required throughout the G1 stage of the cell cycle (Tushinski and 
Stanley, 1985), suggesting that CSF-1 dependent signaling pathway at late G1 
are required for the production, or activation of key proteins that ultimately 
determine the commitment to DNA synthesis. Therefore p96 is thus shown to 
be one of the component in the CSF-1 signal transduction cascade. 
DOC-2 protein is speculated to be involved in signal transduction because 
it shows a high homology to both Dab protein and p96 protein. DOC-2 show a 
high degree of identity in the amino acid sequence with Dab protein (43% 
identity) and p96 (81% identity) in the presumptive PDD (Albertsen et al., 
1996). Evidence of the involvement of DOC-2 in signal transduction is further 
strengthened by the preliminary results done by our group that TGF-P was 
able to inhibit the proliferation of normal ovarian epithelial cell culture with a 
concomitant down-regulation of the expression of DOC-2 at a magnitude of 
over 10 folds. Bi contrast, ovarian cancer cell lines with down-regulation of 
DOC-2 appeared not to response to the addition of TGF-P, which is similar to 
the phenomenon reported by Berchuck et al. (1992). Normal ovarian epithelial 
cells have been reported to produce, activate and are growth inhibited (40-
70%) by TGF-P (Berchuck et aL, 1992). The preliminary results suggested 
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that DOC-2 gene, or its gene products, may be one of the component in the 
TGF_P signal transduction cascade that is responsive to TGF_P in regulating 
the growth and proliferation of normal ovarian epithelial cells. It is 
hypothesized that if the gene products of DOC-2 is an important signal 
transduction molecule, it may also involve in the early embryonic 
development. Dab protein is an example of signalling molecule that is actively 
involved in embryonic development of central nervous system (Gertler et al., 
1993). However, no previous publications have focused on the expression 
pattem of p96 protein in mouse embryos. Li this chapter, an antibody against a 
specific sequence of DOC-2 which is also homologous to the sequence of p96 
was used to detect the expression of the DOC-2 protein in developing mouse 
embryos at different developmental stages. Such investigation may give us 
information on whether the protein with PJD are involved in embryonic 
development. Our pilot study showed that expression of DOC-2 protein was 
particularly strong in the cartilage, brain and kidney. Ln order to further 
investigate the function of the DOC-2 protein in developing organs, the 
embryonic kidney in vitro, and the anti-DOC-2 antibody was used to deplete 
the DOC-2 protein in the culture medium and in the developing kidney to see 
whether there are any effects on the in vitro development of the kidney. 
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3.2 Materials and Methods 
3.2.1 Expression of murine homolog of DOC-2 (p96) during mouse 
embryonic development 
3.2.1.1 Preparation of paraffin-embedded mouse embryo sections 
For studying the expression of DOC-2 protein on mouse embryos, ICR 
mouse embryos of 10.5-17.5 days postconception (i.e. d.p.c.) were collected 
for immunohistochemistry. Pregnant mice were sacrified by cervical 
dislocation. The mouse embryos were then collected as soon as possible and 
were quickly placed into sterilized PBS and washed twice. The embryos were 
then fixed in 4% paraformaldehyde in sterilized PBS ovemight. The embryos 
were washed in PBS twice (5 minutes each) and dehydrated in 70% alcohol, 
through successively 80% alcohol, 95% alcohol and subsequently absolute 
alcohol (twice), then to 1:1 mixture of absolute alcohol and histoclear (twice) 
and finally to histoclear (twice) for complete clearing. For 14.5 d.p.c. or 
younger embryos, each step of dehydration and clearing took 15 minutes 
whereas for embryos larger than 14.5 d.p.c. 30 minutes for each step were 
required. The embryos were then immersed into wax at 58°C to allow wax 
penetration for about 3 hours. After wax penetration, embryos were oriented 
in a sagittal plane and were cooled on a cold plate until the wax was set. 7 i^m 
sections were cut serially using a microtome and the tissue sections were 
mounted on a cleaned TESPA (3-aminopropyltriethoxysilane, Sigma, St Louis, 
“ ^5 
Chapter 3 Materials and Methods 
MO, USA)-coated slides. 
3.2.1.2 Preparation of OCT-embedded (frozen) mouse embryo sections 
ICR mouse embryos were collected and fixed as mentioned above. After 
washing with PBS, the embryos were dehydrated from 10% sucrose through 
20% sucrose and finally 30% sucrose (sucrose were dissolved in O.lM 
phosphate buffer). The embryos were then immersed in O.C.T. embedding 
medium (Miles, Elkhart, lN, USA) overnight at 4°C to allow complete O.C.T. 
penetration. The embryos were orientated in a sagittal plane and then frozen in 
isopropanol just after the isopropanol was precooled in liquid nitrogen. S\xm 
frozen sections were cut using a cryotome and the tissue sections were 
mounted on a precleaned TESPA-coated slides and were stored at -20°C 
freezer. 
3.2.1.3 tomunohistochemistry of murine homolog of DOC-2 (p96) on mouse 
embryos 
For paraffin sections of mouse embryos, the sections were placed in 60°C 
oven for 2 hours. The sections were deparaffinized in xylene and rehydrated 
through graded alcohol and were washed in PBS twice. For frozen sections of 
mouse embryos, the sections were taken from -20�C freezer and then cooled to 
room temperature for 30 minutes. The sections were postfixed in acetone for 5 
minutes and were left air-dried. After washing with PBS, both paraffin and 
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frozen sections were undergone usual immunohistochemical procedures as 
mentioned previously in section 2.2.1. aM2 antisera (i.e. p96 antibody) was 
diluted to 1:4000 for paraffin sections and 1:6000 for frozen sections. 
3.2.2 Effect of antibody blocking for DOC-2 protein on the growth of 
embryonic kidney in vitro 
For an in vitro embryonic kidney culture, embryonic kidneys from 13.5 
d.p.c. mouse embryos were isolated. The pregnant ICR mice were sacrificed 
by cervical dislocation and embryos were collected and were then transferred 
to LEffiOVrrZ's L-15 MEDKJM (L-15 medium, Gibco, NY, USA) (appendix 
WI) for further embryo dissection and kidney isolation. A 6-well culture plate 
(Coming, NY, USA) with an additional 0.4pjn polycarbonate-coated culture 
plate insert (Millipore Corp., MA, USA) inside each culture well was used for 
embryonic kidney culturing. The culture medium used was Dulbecco's 
Modified Eagle Medium : Nutrient Mixture F-12 (Ham) (DMEM/F-12, 1:1， 
with HEPES, Gibco, NY, USA) (Appendix VH) supplemented with 5% fetal 
bovine serum (FBS). The embryonic kidneys were placed in the insert inside 
the culture well with 1.2ml culture medium, and the culture plate was allowed 
to incubate in a 5% CO2 incubator at 37°C for 5-day (the first day of 
incubation was assigned as day 1). aM2 antibody (1:10) was added to the 
culture medium to deplete the endogenous DOC-2 protein expression so as to 
examine the effect of DOC-2 protein on the development of embryonic kidney 
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in an in vitro system, whereas addition of culture medium alone was used as a 
negative control. The culture medium was changed every 2-day, and changing 
of medium was accompanied by the addition of aM2 antibody so as to provide 
sufficient nutrients for the growth of embryonic kidneys and to ensure 
continue blocking of DOC-2 protein expression. The effects of DOC-2 protein 
depletion on the growth of embryonic kidneys were analyzed by comparing the 
changes in size of the cultured kidney under phase contrast microscopy. The 
<«% 
volume of the kidneys was estimated by the following equations V = (L x W ) 
X 0.5, where L be the longest length and W be the shortest width. Besides, any 
morphological changes resulted from protein depletion were examined by 
routine hematoxylin and eosin (H & E) staining. 
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3.3 Results 
The DOC-2 protein expression pattem in mouse embryos was analyzed 
by immunohistochemistry using the aM2 antibody, and the mouse embryonic 
tissues of ICR mice that expressed the DOC-2 protein were summarized in 
table 4. The embryos for immunohistochemical staining were sectioned in 
sagittal plane. 
Expression of DOC-2 protein was indicated by the presence of brown 
reaction products localized in the cytoplasms of cells. The preadsorbed control 
using antibody preadsorbed by specific peptide revealed no positive signal, 
indicating the high specificity of the antibody in binding to the unique 
sequence of DOC-2 protein. It was shown that the DOC-2 protein was 
expressed in mouse embryos. Li addition, the results also showed that the 
protein expression was increased in all the embryonic tissues examined with 
more advanced embryonic stage. The expression found in dorsal root ganglia, 
skin, cartilage primordium, kidney and brain was increased in 17 day 
postconception as compared with that in younger embryonic stages. In 
mesonephric ducts and mesonephric tubules (Fig. 6)，the expression was 
detected in 11 d.p.c. embryos and then increased in intensity in 12 d.p.c.. On 
13 d.p.c., the embryonic organ disappeared and the expression could not be 
detected anymore (Table 3). Expression of DOC-2 protein in mesonephric 
ducts and tubules was localized in the cytoplasm of epithelial cells of the 
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tubules. Whereas the mesonephric component of urogenital ridge showed no 
DOC-2 expression. 
The expression of DOC-2 protein was most intense in all of the cartilage 
primordium (the primitive cartilage). For example in 14 d.p.c. embryos the 
DOC-2 protein was expressed in Meckel ‘ s cartilage, costal cartilage, cartilage 
primordium of hyoid bone, turbinate bone, and basioocipital bone, cartilage of 
limbs, and cartilage along the vertebral column. Fig. 7 showed a 
representative picture of DOC-2 expression in Meckel ‘ s cartilage in 14 d.p.c. 
embryos. Unlike the expression of DOC-2 protein in mesonephric tubules that 
found in the cytoplasm of the epithelial cells, the expression of DOC-2 protein 
was found in the peripheral region of chondrocytes, indicated by the presence 
of brown ring around each chondrocyte. Moreover, DOC-2 protein also 
expressed in the site of ossification. 
The expression of DOC-2 in embryonic brain was initially observed in 14 
d.p.c. embryos, but the intensity was increased with the embryonic stage. 
Lnmunohistochemical detection of DOC-2 protein on frozen sections of 14 
d.p.c. and 17.5 d.p.c. embryonic brains showed significant differences. Figure 
8A showed that the expression pattem of DOC-2 protein in 14 d.p.c. 
embryonic brain appeared like a network between neuronal cell bodies, and the 
brown reaction products were not around the neuronal cell bodies. Therefore 
it was most probable that DOC-2 protein was found in nerve fibers. Similar 
expression pattem was detected during the embryonic development, and in 17 
d.p.c. embryonic brains, DOC-2 was expressed in a similar manner but showed 
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a higher staining intensity and larger area of DOC-2 expression (Fig. 8B). 
DOC-2 protein was mainly localized in cerebral cortex, diencephalon, and 
midbrain. Literestingly, DOC-2 protein was also expressed in hippocampus of 
the adult brain. Jn human and rodent, the hippocampus is situated immediately 
under the temporal hom of the lateral ventricle and is continuous with the 
parahippocampal gyrus. Expression of DOC-2 was confined mainly to CA3 
region and also part of dentate gyrus of the hippocampus in the adult brain 
(Fig.9A). Higher magnification (Fig. 9B) demonstrated that DOC-2 protein 
was found exclusively in pyramidal cells but absent in granular cells. 
Subcellular localization of DOC-2 was, however, inside the nuclei of the 
pyramidal cells (Fig. 9B). Apart from the expression of DOC-2 in pyramidal 
cells, the nerve fibers also expressed DOC-2 protein. 
DOC-2 protein was also expressed in embryonic kidneys from embryos 
of 14 d.p.c. onwards. However, not all the structures of embryonic kidneys 
expressed DOC-2. It was mainly the metanephric (collecting) tubules (Fig. 
10) that expressed DOC-2 protein. Expression was low in structures such as 
Bowman's capsule, glomeruli, fibrous capsule, proximal and distal 
convoluted tubules. Examination of adult kidney showed that DOC-2 protein 
expression was totally absence in adult kidney. 
To investigate whether DOC-2 protein plays a role in the development of 
mouse embryonic kidneys, an in vitro organ culture system for the growth of 
mouse embryonic kidney with the addition of antibody (aM2) specific to 
DOC-2 protein was employed in this studied to deplete the protein in the 
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kidney, lbi the control organ culture, in which only the culture medium 
(DMEMyTF-12, with serum) instead of the ocM2 antibody was added, the 
embryonic kidney gradually increase in the size. When the kidney in vitro was 
assumed to be spherical in shape, the volume of the kidney could then be 
estimated by using the equation V = (L x W^) x 0.5 where V is the volume; L 
is the longest diameter while W is the shortest diameter. Li the control culture, 
there was an increased in size of the kidney on the first day of the culture, but 
the growth rates as reflected by the slope of the curve in Graph 5 appeared to 
slow on days 2 and 3 although a slight increase in the size of the kidney was 
still observed on day 3 as compared with the size on day 1. From day 4 
onward, the size started to increase exponentially (Graph 5). Li the antibody-
treated culture, although the size of the kidney was slightly increased on day 1， 
it was not increased as quickly as the control kidney (Graph 5). From day 2 to 
day 4，the size was slightly reduced but the size was a slightly larger than the 
initial size. From day 4 onward, as was observed in control culture, the size 
was increased more quickly but the extent of the increase in size was 
significantly lower than that of the control kidney (Graph 5). During the 
whole culture period, the in vitro growth of the antibody-treated explants was 
slower than that of the control kidney and on day 4，the size of the control 
kidneys were on average 2 folds larger than that of the treated kidneys. As 
observed under phase contrast microscope, the control and treated kidneys 
were approximately same in size initially (Fig. 1 lA and 1 lB). On day 2，the 
control kidney showed an increase in size (Fig. 1 lC) which had already larger 
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than the treated kidney (Fig. 1 lD). On day 4，the size of the control kidney 
was nearly two times as large as the treated kidneys (Fig. 12A and 12B). As 
the culture reached day 5, the control kidney showed a two-fold larger in size 
when compared to the treated kidneys (Fig. 12C and 12D). When the cultures 
were examined histologically after frozen sectioning and hematoxylin and 
eosin staining, the tubules in the antibody-treated kidney appeared to be 
histologically normal (Fig. 13A) as compared with the control kidney (Fig. 
13B). 
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3.4 Discussion 
To investigate whether the DOC-2 protein that accommodates the FJD 
(Phosphotyrosine &iteraction Domain) was involved in embryonic 
development, immunohistochemistry using an anti-DOC-2 antibody 
specifically against a unique sequence of DOC-2 was performed to study the 
expression pattem of DOC-2 protein during mouse embryonic development. 
Results indicated that DOC-2 protein was expressed during mouse embryonic 
development. The expression appeared to increase in intensity and more 
structures became positive as development proceeds. Expression was 
obviously seen in almost all the cartilage primordium of mouse embryos, 
suggesting that DOC-2 protein may involve in the development of cartilage. 
However, the expression of DOC-2 protein or other homologue with PDD in 
embryonic cartilage had not been reported previously. Subsequent 
experiments have to be done to investigate the role of DOC-2 in the 
development and its function during chondrogenesis. 
Apart from DOC-2 the expression in embryonic cartilages, DOC-2 
protein was also expressed in embryonic brain. Expression was mainly 
localized in cerebral cortex, diencephalon and midbrain. The expression 
appeared to be found in nerve fibers rather than cell bodies. It was interesting 
to note that recent publications had reported the presence of PE)-containing 
protein in tissues of nervous system (Gertler et al., 1993; Albertsen et al., 
1996; Howell et al., 1997). For example, the disabled gene product (dab), 
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which contains a PE) and showed a 46% identical amino acid sequence with 
the DOC-2 protein, was found to express during development of the central 
nervous system in Drosophila (Gertler et al., 1993). dab was present 
throughout the development of Drosophila until later in development, where 
the expression in the central nervous system was concentrated in the axon 
bundles. The findings by Albertsen et al. (1996) demonstrated that cDNA 
clones of human DOC-2 protein were isolated from a brain-stem library, 
suggesting that DOC-2 protein itself may have a role to play in human central 
nervous system. Furthermore, Howell et al. (1997) have recently identified 
another mouse homolog of dab, mDab 1，that also contains a PDD domain. 
mDab 1 showed tyrosine phosphorylation activity during mouse 
embryogenesis when the nervous system was undergoing dramatic expansion 
suggesting that mDab 1 has important function in the formation of neural 
networks. Together with our findings that the DOC-2 protein was expressed 
in embryonic brain, it was suggested that molecules with FJD may play an 
important role in the development of nervous systems in different species. Jn 
addition, DOC-2 protein was not only found in mouse embryonic brain but 
also expressed in adult hippocampus which was suggested to be an important 
structure for memory. The hippocampus appears as a curved cortical structure 
in the floor and medial wall of the temporal hom of the lateral ventricle. Li 
rodents, lesions in hippocampus can result in deficits in behavioral ability 
(Olton, 1983). The specific expression pattem of DOC-2 in adult 
hippocampus may play a role and is worth further investigation. 
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The DOC-2 protein expression was also observed in embryonic kidneys 
beginning at stage 14 d.p.c. onward. The majority of expression was localized 
in the metanephric (collecting) tubules of the embryonic kidneys, but absent in 
adult kidneys. On the other hand, using an in vitro embryonic kidney culture 
system with the addition of antibody that depleted the DOC-2 function, the 
growth of kidneys seemed to be retarded. However, the hematoxylin and eosin 
staining did not show obvious histological defects of the intemal structures of 
the kidney when the kidney was treated with the antibody and there was no 
sign of poor differentiation of kidney tubules. Therefore the DOC-2 protein 
may be important in the normal growth, rather than the differentiation, of 
kidney during the embryonic stage, and the expression of the DOC-2 protein 
was no longer necessary for an adult mouse kidney. 
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Chapter 4 Apoptosis 
4.1 Introduction 
Apoptosis was originally defined and distinguished from other types of 
cell death on the basis of its ultrastructure (Kerr et al.’ 1972). Li 1980，Wyllie 
et al. proposed formally a new classification of cell death based on 
morphological criteria which distinguish the destructive, degenerative 
phenomenon known as necrosis from the second cell death in which the dying 
cells undergo a progressive contraction of cellular volume, widespread 
chromatin condensation, but preservation of cytoplasmic organelles. The cells 
are then fragmented into a number of membrane-bound bodies which are 
engulfed or phagocytosed rapidly by neighboring cells. Such cell death is 
termed apoptosis. 
Morphologically, apoptotic cells are easily recognizable. At the light 
microscope level, apoptotic cells occur individually or in very small groups 
which are widely dispersed amongst viable cells. The earliest intracellular 
changes observed from electron microscopy are condensation of the cytoplasm 
and margination of nuclear chromatin that abut on the nuclear membrane. 
Large apoptotic cells appear shrinkage at this stage. It is followed by nuclear 
fragmentation and budding of the cell and ultimately the cell breaks up into 
fragments called apoptotic bodies which are membrane-bound and therefore 
— 
Chapter 4 Introduction 
induces no inflammatory response. The integrity of organelles is largely 
maintained without signs of swelling in the cistemae of endoplasmic 
reticulum. Apoptotic bodies are rapidly phagocytosed by macrophages and 
neighboring cells and thus most often the vast majority of the apoptotic bodies 
are already phagocytosed within the neighboring cells in the time of 
investigation (Alison and Sarraf, 1992). It is estimated that the apoptotic 
bodies remain visible by light microscopy for only a few hours. Once inside 
the ingesting cell, the apoptotic body is safely packaged in the heterophagic 
vacuoles and is undergone fusion with lysosomes which is then rapidly 
degraded by a process similar to necrosis (Alison and Sarraf, 1992). Jn 
contrast, the ultrastructures of necrosis are quite different. Early signs of 
necrosis include clumping of chromatin into ill-defined masses, gross swelling 
of organelles, and ultimately destruction of membrane integrity and 
disintegration of the cell resulted. Necrosis occurring in vivo is usually 
accompanied by exudative inflammation and, if large numbers of cells are 
involved, is often followed by the development of a scar. 
Li addition to the morphological difference between apoptosis and 
necrosis, the underlying biochemical mechanism between the two are also 
discorded. The most extensively studied biochemical event in apoptosis 
involves the fate of nuclear DNA (Kerr and Harmon, 1991). Necrosis occurs 
with a random DNA digestion, whereas apoptosis is always involved a specific 
manner of DNA cleavage, which appears responsible for the characteristic 
nuclear morphological changes (Alison and Sarraf, 1992). In eukaryotic cells 
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the DNA double helix in each chromosome is folded in a highly ordered 
fashion. The fundamental unit of DNA packing is the nucleosome, a histone 
octamer consisting of two copies of each of four histone proteins which are 
small proteins with a high proportion of positively charged amino acids 
(Eamshaw, 1995). The nucleosome forms a protein core around which the 
double stranded DNA helix is wrapped twice. Since examinations of DNA 
cleavage in thymocytes undergoing apoptosis by means of agarose gel 
electrophoresis revealed a regular ''laddering pattem" of 200-300-bp 
fragments, which appears to be attributed to the digestion of the chromatin 
between nucleosomes. This strongly suggested that specific endocucleases 
rather than proteases are involved in DNA cleavage (Wyllie, 1980). There are 
two phases of DNA digestion during apoptosis. The first involves cleavage of 
the genome into 200-300-bp and 30-50 kb pieces. The second phase involves 
further cleavage between nucleosomes that produces fragments in multiples of 
approximately 185-bp (Wyllie, 1980). The activation of endonucleases is 
dependent upon cytosolic Ca�+ and Mg�+ concentration (Cohen and Duke, 
1984). The two cleavages appear to be responsible for by two types of 
nucleases (Eamshaw, 1995). 
4.1.1 Current method for the detection of apoptosis 
There are several methods which are currently used to detect the 
occurrence of apoptosis. They are the agarose gel electrophoresis, flow 
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cytometric analysis, 3 ‘ -OH end labelling, and the analysis of endonucleases. 
4.1.1.1 Agarose gel electrophoresis 
Based on the specific manner of DNA cleavage occurred in apoptosis, the 
agarose gel electrophoresis is most often employed to analyze the DNA 
fragmentation in nuclear extracts. The occurrence of apoptosis is indicated by 
the presence of the typical �DNA ladder ‘ configuration (Compton and 
Cidlowsky, 1986). An improved method for the detection of DNA 
fragmentation visualizes the DNA after Southem blotting with a radiolabelled 
total cellular DNA probe instead of ethidium bromide staining. This method 
increases the sensitivity of detection (Facchinetti et al., 1991). Another 
method to measure low levels of DNA cleavage is based on the labelling of the 
free 3 ‘ -OH end of nicked DNA with ^^-dATP or ^^-dCTP mediated by 
Klenow polymerase, followed by agarose gel electrophoresis and 
autoradiography (Rosl, 1992). However, this method is time-consuming, 
requires a great number of cells for DNA extraction, involves exposure to 
32 
hazardous P，and is unable to determine the percentage of apoptotic nuclei 
nor recognize the apoptotic cells in a heterogeneous cell population (Sgonc 
and Wick, 1994). A more sensitive, quicker and cheaper assay, JAM test, was 
introduced for the detection of apoptosis in proliferating cells. This assay is 
based on the DNA fragmentation which is an early event in apoptosis induced 
by cytotoxic T cells. The target cells are labelled with less hazardous [^U]-
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thymidine. The cells are then lysed and harvested onto fiberglass filter after 
incubation with cytotoxic T cells. Small pieces of fragmented DNA are 
washed through the filter, leaving only the intact DNA on the filter. This 
method is more sensitive, less hazardous, quicker, and cheaper than the ^^Cr 
release assay for detecting cytotoxicity. 
4.1.1.2 Flow cytometric analysis 
Flow cytometric analysis, can be used for studying DNA degradation in 
cells undergoing apoptosis (Darzynkiewicz et al., 1992). As activation of 
endonucleases in apoptotic cells leads to DNA fragmentation and subsequently 
to extensive DNA loss, apoptosis can be determined by the simple 
measurement of the DNA content with flow cytometer using intercalating 
DNA dyes, such as PI (propidium iodide), ethidium bromide, and acridine 
orange, or dyes binding externally to DNA, such as Hoechst 342 (Ho342), 
DAPI (4'-6-diaminido-2-phenyl indole), and mithramycin (Telford et al., 
1992). The easiest and most rapid way for measuring apoptosis is DNA 
staining with a hypotonic PI solution (Nicoletti et al., 1991). For the analysis 
of viable cells undergoing apoptosis, staining with Ho 342，which diffuses 
through cell membranes and appeared as bright blue fluorescence under 
fluorescence microscopy, is recommended (Hardin et al., 1992). Moreover, a 
combination of staining with Ho 342 and a PI / phosphate-buffered saline 
solution that does not diffuse through intact cell membranes allows 
discrimination among, and quantitation of, apoptotic, necrotic, and viable cells 
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(Dive et al., 1992; Sun et al., 1992). Based on the morphological changes in 
apoptosis, changes in size and granular content of apoptotic cells can also be 
observed under a flow cytometer. Apoptosis is characterized by water loss, 
cell shrinkage, and nuclear fragmentation, which do not occur in necrosis. 
Therefore, apoptotic cells and necrotic cells differ in light scattering pattem 
under a flow cytometer (Carbonari et al., 1994). Apoptotic cells can also be 
distinguished from viable cells in which apoptotic cells give lower forward 
scatter and higher side scatter values than viable cells, reflecting the smaller 
size and different nucleus/cytoplasm consistency. Unfortunately, such 
morphological changes are not consistent in all cell types (Sgonc and Wick, 
1994). 
4.1.1.3 3 ‘ -OH end labeling 
DNA strand breaks resulting from activation of endonucleases in 
apoptotic cells can be labelled in situ in fixed, permeabilized cells or in tissue 
sections by the terminal deoxynucleotidyl transferase mediated dUTP nick end 
labelling (TUNEL) technique (Gavrieli et al., 1992). The 3 ' -OH ends of 
DNA fragments can be labeled with either biotin-dUTP, digoxigenin-dUTP, or 
FrrC-dUTP. Among the three, FFTC-dUTP，although less sensitive than the 
others, generates the lowest background staining (Sgonc and Wick, 1994). 
The 3 ‘ -OH end labelling technique enables quantitation of the percentage of 
apoptotic cells in heterogenous population and reveals early DNA breakage 
during apoptosis. 
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4.1.1.4 Nuclease assay 
The target of this assay is to detect the DNA-degrading activity in sodium 
dodecyl sulfate-polyacrylamide gels in which a nonradioactive or ^^P-labelled 
nucleic acid substrate is incorporated into the gel matrix, and nuclease activity 
is measured by the loss of the substrate from the gel (Rosenthal and Lacks, 
1977). This assay is simple but lacks the specificity to detect intemucleosomal 
DNA degradation. Therefore another nuclease activity assay was developed 
specifically to study nucleases cleaving DNA at intemucleosomal sites. The 
assay utilizes nuclei of HeLa or chicken red blood cells (not susceptible to 
glucocorticoid-induced lysis) as substrate. After incubation of HeLa or 
chicken red blood cell nuclei with glucocorticoid-treated thymocytes nuclear 
protein extracts, the DNA is isolated from the nuclei and analyzed by agarose 
gel electrophoresis which allows differentiation between random DNA 
degradation and intemucleosomal cleavage (Compton, 1991). 
4.1.2 Apoptosis in normal physiology and oncogenesis 
Large numbers of cells can be eliminated from living tissues by apoptosis 
without significant disturbance of the overall tissue architecture (Alison and 
Sarraf, 1992). The process is frequently observed in physiological events for 
example in developmental growth, in normal cell tumover and in maintaining 
homeostasis within the immune system. Apoptosis plays a vital role in the 
embryonic development of higher vertebrates. It plays a major morphogenetic 
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role in the patterning of limbs and interdigital clefts (Kerr et al., 1987)， 
formation of palate (Ferguson, 1988), establishment of correct neuronal 
circuitry (Snow, 1987), etc. On the other hand, apoptotic deletion of 
lymphocytes serves important functions in the immune system. Lnmature 
thymocytes have been shown to undergo apoptosis upon stimulation via their 
T cell receptor at a critical stage in their maturation (Kerr and Harmon, 1991)， 
and it has been proposed that apoptosis is the mechanism responsible for the 
negative selection process which is thought to involve interaction between 
antigen-specific T cell receptor and self-antigen presented by the MHC 
proteins on accessory cells. The negative selection process results in the 
elimination of autoreactive T-cell clones during the development of cellular 
immune self-tolerance. Apoptosis also accounts for the cell deletion that 
accompanies a variety of normal involutional processes including ovarian 
follicular atresia, catagen involution of hair follicles, and regression of the 
lactating breast after weaning (Kerr and Harmon, 1991). Furthermore, after 
inflammation, neutrophils undergo apoptosis, and associated cell surface 
changes aid their phagocytosis by macrophages (Savill et al., 1989). 
In the past, cancer was usually thought to be arisen from an uncontrolled 
cell proliferation. However, the cell number in a structure is a result of the 
balance between cell proliferation and cell death. Hence, recently many cancer 
biologists focus on the role of cell death, especially apoptotic cell death, in 
human oncogenesis. The idea that apoptosis is thought to be of particular 
importance in this regard is further strengthened by at least three observations. 
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The first is that most physical and chemical agents, which are shown to have 
anti-tumor activity, are able to induce apoptosis (Martin and Green, 1995). 
The second is that the occurrence of apoptotic cells in a tumor correlates very 
well with malignancy. Tumors with low apoptotic indices tend to be more 
aggressive than are those demonstrating high incidence of apoptotic cell death 
(Arends et al., 1994). The third observation is that a number of oncogenes and 
anti-oncogenes have been found to regulate the process of apoptosis 
(Bissonnette et al., 1994). p53 and bcl-2 are two genes that are well known of 
actively involved in the process of apoptosis. 
4.1.3 p53 and apoptosis 
The apoptosis induced by radiation or other DNA damaging agents is 
regulated by p53. Cells from p53 deficient mice are unable to undergo 
apoptosis induced by ionizing radiation {JR) (Lee et al., 1994) or by 
chemotherapeutic drugs 5-fluorouracil, ectoposide and adriamycin (Lowe et 
al.，1993). The fact that apoptosis proceeds even in the presence of 
transcriptional and translational inhibitor such as cycloheximide and 
actinomycin D (Caelles et al., 1994) suggests that p53 might promote 
apoptosis by binding to and directly activating the various cellular proteins 
required for apoptosis or suppress transcription of other apoptosis-inhibiting 
factors (Lee and Bemsstein, 1995). It is unclear whether p53-mediated 
apoptosis and p53-mediated Gl/S cell cycle arrest are related. However, 
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actively involved in the process of apoptosis. 
4.1.3 p53 and apoptosis 
The apoptosis induced by radiation or other DNA damaging agents is 
regulated by p53. Cells from p53 deficient mice are unable to undergo 
apoptosis induced by ionizing radiation (JR) (Lee et al., 1994) or by 
chemotherapeutic drugs 5-fluorouracil, ectoposide and adriamycin (Lowe et 
al., 1993). The fact that apoptosis proceeds even in the presence of 
transcriptional and translational inhibitor such as cycloheximide and 
actinomycin D (Caelles et al., 1994) suggests that p53 might promote 
apoptosis by binding to and directly activating the various cellular proteins 
required for apoptosis or suppress transcription of other apoptosis-inhibiting 
factors (Lee and Bemsstein, 1995). It is unclear whether p53-mediated 
apoptosis and p53-mediated Gl/S cell cycle arrest are related. However, 
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Johnson et al. (1993) found that in those cells undergoing p53 mediated 
apoptosis, the ability to enter into apoptosis is independent of their position in 
the cell cycle. Thus, the Gl/S arrest and apoptosis mediated by p53 represent 
divergent biological pathways. The contradictory findings from Yonish-
Rouach et al. (1993) were that a hematopoietic cell line with temperature 
sensitive p53 mutant at 32.5°C failed to elicit a G1 arrest in the absence of 
growth factor, and these cells continued to progress through the cell cycle and 
underwent apoptosis. Synchronized cells residing in G1 upon temperature shift 
appeared to die more rapidly when compared to cells in other phases of the cell 
cycle, indicating that the commitment to the undergo cell death takes place 
preferentially in G1 and subsequent failure to growth arrest is associated with 
apoptosis. 
The cellular consequence after infra-red (ER) activation of p53 would be 
cell-type specific. This was supported by the evidence that cells such as 
fibroblasts tend to undergo cell cycle arrest after irradiated by IR, while cells 
such as hematopoietic cells tend to undergo apoptosis after JR (Slichenmyer et 
al., 1993). Liduction of p53-mediated G1 growth arrest and apoptosis were not 
documented to occur in a particular cell type as a result of the same stimulus. 
The divergence of growth arrest and apoptosis was also observed in the 
myeloblastic leukemia Ml cell line, which is null for p53 expression. It was 
shown that introduction of a p53 temperature sensitive mutant transgene 
(p53ts) (p53 retains its mutant conformation at 37°C but displays a wild-type 
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form at 32.5°C), enables the cell line to have function of p53, i.e. promoting 
rapid apoptosis. When the cell line was subjected to high level of ectopic bcl-
2 expression, G1 growth arrest was resulted and apoptosis was delayed 
(Selvakumaran et al., 1994). At the molecular level, It was shown that events 
which took place early during the p53-induced G1 arrest (i.e., decrease in the 
expression and kinase activity of cyclin A, dephosphorylation of pRb and 
pl07) occurred both in the Mlp53 and in the Mlp53/bd-2 cells, whereas late 
events (i.e., inactivation of the kinase activities of cyclin E, cdk2 and cdc2) 
occurred only in the Mlp53/bcl-2 cells. The Mlp53/bcl-2 cells underwent 
delayed apoptosis, thereby allowing the cells to complete G1 arrest. These 
findings demonstrated that wildtype p53 can simultaneously induce the genetic 
programs of both growth arrest and apoptosis within the same cell type, in 
which the genetic program of cell death can proceed in either Gl-arrest 
(Mlp53/bcl-2) or cycling (Mlp53) cells, and the outcome of p53 activation in 
a given cell type is dependent on its ability to induce G1 arrest and/or 
apoptosis, as well as the relative kinetics of these processes. Miyashita et al. 
(1994b) examined the interaction between the transfected temperature 
sensitive mutant p53 ^ and the endogenous bcl-2 in Ml cells at permissive 
temperature (i.e. 32.5°C ). The relative level of bcl-2 mRNA decreased with 
increased incubation time, before significant cell death was detected in these 
cultures, whereas the cells without transfected p53 ^^  mutant showed no bcl-2 
reduction. Accompanied with bcl-2 reduction is an increase in the relative 
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level of bax mRNA. The ratio of bcl-2 and bax proteins is thought to regulate 
relative susceptibility of cells to the stimulation of apoptotic cell death (Oltvai 
et al., 1993). Wang et al. (1993) also reported that over-production of bcl-2 
protein can abrogate p53-induced apoptosis, suggesting that high levels of bcl-
2 protein protect cells from p53 induced apoptosis. Similar claim was made 
by Marin et al. (1994)，in which overexpressed bcl-2 suppressed wild-type p53 
associated apoptosis following y-radiation, suggesting that bcl-2 is one of the 
p53 regulatory gene involved in a common cell death pathway. On the other 
hand, Eliopoulos et al. (1995) reported that transfection of bcl-2 rescued 
ovarian cancer cell line from drug induced apoptosis in the presence of a 
transfected temperature-sensitive p53 mutant and delayed drug-mediated S-
phase arrest, speculating that bcl-2 may act upstream of the p53 pathway. 
The decision making of whether a cell, subjected to DNA damage, will 
enter G1 arrest or enter apoptosis is still not yet fully understood. One 
attractive hypothesis suggests that G1 arrest provides an opportunity for the 
cell to repair before DNA replication take place (Lotem and Sachs, 1993). 
When the damage is irreparable, apoptosis will be triggered to prevent 
replication of damaged DNA and avoid a gradual accumulation of genetic 
defects that might result in carcinogenesis. 
4.1.4 bcl-2 and apoptosis 
The first fact that indicates defects in the cell death pathway can lead to 
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the development of human neoplasia come from the discovery of the bcl-2 
gene (Tsujimoto and Croce, 1986; Vaux et al., 1988). The bcl-2 gene, the 
acronym for the "B-cell lymphoma>1eukemia-2 “ gene, was first discovered for 
its frequent involvement in B-cell malignancies, where chromosomal 
translocations activate the gene in the majority of follicular non-Hodgkin ‘ s B-
cell lymphomas (Tsujimoto et al., 1985). ln these translocations, the bcl-2 
gene is moved from its normal chromosomal location at 18q21 into 
juxtaposition with powerful enhancer elements in the immunoglobulin heavy-
chain (IgH) locus at 14q32, with the result of being deregulation of the 
translocated bcl-2 gene and over-production of bcl-2 mRNAs and their 
encoded proteins (reviewed by Nowell and Croce, 1987). Such translocations 
may be the consequence of errors in the normal DNA recombination 
(Tsujimoto et al., 1988). It is estimated that approximately 90% of low-grade 
non-Hodgkin ‘ s lymphomas, as well as about 30% of more aggressive B-cell 
lymphomas involved the bcl-2 gene activation (Reed et al., 1996). 
Vaux et al. (1988) were the first to report that bcl-2 can prolong cell 
survival. These investigators transferred the stable bcl-2 expression vectors in 
immature pre-B-cells that were EL-3 (Literleukin-3)-dependent. When 
subjected to the setting of EL-3 withdrawal, the pre-B-cells underwent cell 
death. The results showed that the expression of exogenous bcl-2 expression 
permitted prolonged cell survival in the absence of E^-3, but without 
concomitant cell proliferation. Since it was known that EL-3 and several other 
colony stimulating factors help to maintain hematopoietic cell survival in vitro 
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by preventing apoptosis (Williams et al., 1990)，the ability of bcl-2 to prolong 
EL-3 dependent hematopoietic cells suggests that bcl-2 was capable of 
blocking apoptosis. Li accordance to the prolonged cell survival observed 
when the levels of bcl-2 protein are elevated through gene transfer technique, 
antisense blocking of bcl-2 gene expression have been shown to accelerate the 
rate of cell death in the setting of growth factor withdrawal (Reed et aL, 
1990a,b). In addition to growth factor withdrawal, over-expression of bcl-2 
can prevent or markedly reduced apoptotic cell death induced by a wide 
variety of stimuli including Gamma- and UV-radiation, chemotherapeutics 
drugs, heat shock, calcium ionophores, free radicals, tumor necrosis factor 
(TNF), and p53-mediated apoptosis, etc (reviewed by Reed, 1994). 
Subcellular location of bcl-2 and involvement of Ca�+ in apoptosis make 
an attractive hypothesis that bcl-2 might mediate apoptosis through Ca^ + 
regulation. The most recent observations based on the use of confocal, laser 
scanning, and electron microscopy suggest that bcl-2 resides in the nuclear 
envelope, parts of the endoplasmic reticulum (ER), and outer mitochrodrial 
membrane but not in other intracellular membrane compartments such as 
plasma membrane (Krajewski et al., 1993). Ca�+ plays an important role in 
apoptosis in which intemucleosomal nucleases responsible for DNA 
degradation are Ca^^-dependent (Cohen and Duke, 1984). The major storage 
sites for Ca�+ are the space between inner and outer nuclear membrane, the 
lumen of the ER, and mitochondria, which are similar to the subcellular 
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location of bcl-2. The association between bcl-2 and Ca�+ was shown by the 
fact that bcl-2 block apoptosis induced by Ca^^-ionophores in thymocytes, T-
cell leukemia lines, and PC12 cells. Fluorometric measurements of cytosolic 
free Ca�+ concentrations in ionophore-treated PC12 cells have revealed that 
over-production of bcl-2 does not prevent rises in intracellular Ca�+ levels, 
suggesting that bcl-2 blocks an apoptotic signal downstream of this event 
(Zhong et aL, 1993). Baffy et al. (1993) also focused on the stores of Ca^^ 
sequestered in the ER and in mitochondria in EL3-dependent cells derived of 
lymphokine. Growth factor withdrawal led to a gradual loss of Ca�+ from the 
ER and a rise in the relative amounts of Ca^^ in the mitochondria. 
Transfection of bcl-2 gene resulting in an elevated bcl-2 protein level 
prevented the alterations in Ca�+ and suppressed apoptotic cell death. These 
data suggest that bcl-2 can either directly or indirectly influence Ca^ + 
partitioning that occurs upon growth factor removal. Supporting this 
hypothesis are the observations that: i) bcl-2 is very effective at blocking 
glucocorticoid- and Ca^^-induced cell death (Miyashita and Reed, 1992, 1993); 
ii) glucocorticoid-treatment of T-cells has also been shown to result in a 
massive loss of Ca]+ from the ER prior to apoptotic cell death, suggesting that 
depletion of ER pool of Ca�+ may be a common phenomenon for apoptosis; 
iii) over-expression of an ER Ca�+ binding protein calbindin D28K in 
glucocorticoid sensitive T-cell delays apoptosis induced by dexamethasone, 
forskolin and A23187, presumably by allowing the ER to retain its Ca:+ and 
— 
Chapter 4 Introduction 
iv) poisoning the Ca^^-ATPase of the ER with thapsigargin induces apoptosis 
(Lam et al., 1993; Dowd et al., 1992). Therefore, it is proposed that 
withdrawal of growth factors in an EL-3-dependent cell line causes a 
redistribution of calcium from non-mitochondrial (e.g. ER) to mitochondrial 
stores, and whereas this redistribution is inhibited by over-expression of bcl-2 
(Craig, 1995). 
An important breakthrough in understanding bcl-2 function and its 
regulation has been the discovery of a family of bcl-2-related genes which 
exhibit sequence similarity in the carboxyl region (Williams and Smith, 1993). 
iiterestingly, several of these bcl-2-related proteins can physically interact 
with each other in the form of homo-and hetero-dimers or oligomers. 
Furthermore, some of these homologs function as blockers of cell death, 
whereas others are promotors of apoptosis. At present, six other mammalian 
homologs of bcl-2 have been reported, including bax, bcl-X, Mcl-l，Al, bad, 
and bak. bcl-X is one member of the bcl-2-family having two alternatively 
spliced forms, bcl-X-L (the long arm) and bcl-X-S (the short arm), which are 
both involved in apoptosis. However, they have opposing effects, with bcl-X-
L acting as a cell death inhibitor and bcl-X-S as a promotor for apoptosis 
(Boise et al., 1993). In addition to bcl-X-L, the Mcl-l (Kozopas et al., 1993) 
and Al (Lin et al., 1993) proteins appear to be suppressors of cell death. 
Conversely, the bax (Oltvai et al., 1993)，bad (Yang et al., 1995) and bak 
(Chittenden et al., 1995) proteins promote apoptosis. All the gene products of 
the members belonging to bcl-2 gene family share two highly conserved 
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domain designated by bcl-2-homology regions (BH1 and BH2) within the 
carboxyl region, each contains about 16 amino acid residues (Yin et al., 1994). 
These two domains contain a central glycine, which is followed by an arginine 
in BH1 and by tryptophan in BH2. These two domains are thought to function 
in the heterodimerization of bcl-2 and bax. The discovery of heterodimer 
formation between bcl-2 and bax came from the coimmunoprecipitation of bax 
with bcl-2 (Oltvai et al., 1993). Mutations in these regions of bcl-2 by creating 
a single amino acid substitution, particularly in a conserved glycine in BH1 
and a conserved tryptophan in BH2, disrupt both heterodimerization with bax 
and cell survival function. Curiously, bcl-2 homodimerization is not affected. 
This mutant bcl-2 had lost its survival function, suggesting that bax-bcl-2 
heterodimerization is essential for bcl-2 function. The relative amounts of bcl-
2 and bax determine the viability of the cell during growth factor deprivation; 
an increase in the amount of bcl-2 relative to bax promoting survival and 
increase in the amount of bax promoting death (Oltvai et al., 1993).The 
opposing cellular functions of bax and bcl-2 have suggested the possibility that 
one dimer partner acts as a dominant negative inhibitor of the other partner ‘ s 
active function. Li addition to overall similarity in the carboxyl region, many 
of the genes in the bcl-2 family have a hydrophobic tail at their extreme 
carboxyl terminus. This tail consists of 19-24 non-charged amino acid 
residues, which are usually flanked by positively-charged residues. This 
hydrophobic tail allows bcl-2 to associate with membranes (Chen-Levy and 
Cleary, 1990). It is the carboxyl hydrophobic tail that targets bcl-2 to the outer 
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mitochondrial membrane, orienting the protein such that the amino terminus 
faces the cytoplasm (Nakai et al., 1993). The effect of bcl-2 on cell survival is 
reduced with the removal of the carboxyl tail, but can be restored by 
replacement with an alternative membrane-spanning region (Hockenbery et al., 
1993). However, removal of the tail did not abolish completely the effect of 
bcl-2 (Hockenbery et al., 1993). It was suggested that the hydrophobic tail, 
while not directly participating in cell viability function of bcl-2, might target 
the protein to a location optimal for activity. The potential mechanism for bcl-
2 on inhibiting cell death can also reveal its ability to confer resistance towards 
drugs-induced apoptosis (Miyashita and Reed, 1992). Indeed, bcl-2 provides 
protection against a wide variety of anti-cancer drugs which have markedly 
diverse mechanism of action, suggesting that they all commit the same final 
pathway for ultimately inducing cell death and that bcl-2 is a blocker of this 
pathway (Reed et al., 1996). However, bcl-2 appears not to interfere with the 
ability of drugs to enter cells to bind to their appropriate targets, and to induce 
damage. Actually, bcl-2 does not protect cancer cells from drug-induced cell 
cycle arrest but does prolong their survival during this period so that 
proliferation can resume upon withdrawal of the drugs. On the other hand, 
rates of DNA repair are also not affected by bcl-2. Thus, although the drugs 
induced cell cycle arrest and damage to DNA, this damage somehow is not 
translated effectively into signals for cell death. Apart from the speculated 
mechanisms of bcl-2 on blocking apoptosis (i.e., regulation of calcium 
partitioning and preventing bax from inducing apoptosis), other possible 
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mechanisms of bcl-2-mediated cell survival include participation in protein 
transport across biological membranes (reviewed in Reed, 1994), regulation of 
proteases (Miura et al., 1994) and physical association with signal transduction 
proteins e.g. GTPase R-Ras and the serine/threonine kinase Raf-1 (Wang et al., 
1994) etc. 
Although bcl-2 was first discovered in non-Hodgkin ‘ s lymphomas, high 
levels and aberrant patterns of bcl-2 gene expression have been reported in a 
wide variety of human cancers, including approximately 90% of colorectal, 
60% of gastric, 30-60% of prostate and 20% of non-small cell lung cancers, 
30% of neuroblastomas, variable percentage of melanomas, renal cell and 
thyroid cancers as well as acute and chronic lymphocytic and non-lymphocytic 
leukemia (reviewed in Reed, 1994). The dysregulation of bcl-2 expression by 
the loss of p53 tumor suppressor gene may be one of the potential role for the 
high expression of bcl-2 in a wide range of human cancers. Loss of p53 
function occurs in about one-half of all human cancers. This DNA-binding 
protein can both induce cell cycle arrest and promote apoptosis and functions 
at least in part as a transcriptional regulator. Jn experiments where p53 
function was conditionally restored to a p53-deficient murine leukemic cell 
line, p53 was shown to induce marked reduction in bcl-2 expression followed 
by apoptotic cell death (Miyashita et aL, 1994a). When bcl-2 protein levels 
were maintained at high levels through gene transfer manipulations, p53-
induced apoptotsis was partially blocked but cell cycle arrest occurred 
normally (Selvakumaran et al., 1994). y-radiation, a known inducer of p53, 
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has also been shown to down-regulate bcl-2 mRNA levels in a human 
leukemic cell line (Zhan et al., 1994). Thus p53 either directly or indirectly 
appears to be able to suppress bcl-2 gene expression, leading to the speculation 
that p53 loss in human tumors may contribute to the high levels and abnormal 
patterns of bcl-2 protein production observed in many types of cancer. Lideed, 
using reporter gene assays, the 5 ‘ -untranslated region of the bcl-2 gene was 
shown to be negatively regulated by p53 (Miyashita et al., 1994b). Therefore 
points should be noted in which i) apoptosis occurred in some settings with 
deficient in wild-type p53 suggests the presence of p53-independent pathway 
for apoptosis; ii) loss of p53 resulted in the dysregulation of bcl-2 expression 
was seen in only some tissues indicates that p53-independent mechanisms for 
bcl-2 expression do occur. 
The aim of this chapter was to investigate the occurrence of apoptosis, 
which was detected by in situ TUNEL labeling, in normal ovaries and various 
ovarian epithelial tumors (benign, borderline and malignant). Jn addition, 
expression patterns of p53 and bcl-2 proteins in normal ovaries and ovarian 
tumors were also examined to see whether they were involved in ovarian 
carcinogenesis and interacted through the process of apoptosis. 
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4.2 Materials and Methods 
4.2.1 Expression of p53 and bcl-2 in human ovarian tissues 
4.2.1.1 Preparation of specimen 
Fresh ovarian tissue samples, including 14 normal ovaries, 7 benign 
ovarian tumors, 29 borderline and 62 invasive epithelial ovarian tumors were 
obtained from the Brigham and Women ‘ s Hospital, Harvard Medical School. 
Patient ‘ s consent was obtained prior to the collection of surgical materials. 
The tissues processing and histopathological diagnosis was the same as that 
described in section 2.2.1. The 14 normal ovarian tissues were included in the 
study for comparison and were obtained from patients with other 
gynecological diseases. 
4.2.1.2 Immunohistochemical studies of the expression of p53 and bcl-2 
proteins in ovarian tissues 
For identification of p53 and bcl-2 proteins, the Avidin-Biotin peroxidase 
Complex (ABC) method was employed. Lnmunohistochemistry was 
performed with the ABC Vectastain kit (Vector Laboratories, Bulingame, CA, 
USA) according to the supplier's protocol. Serially 7-p,m sections were cut 
with a microtome, mounted on Superfrost /Plus microscope slides (Fisher 
Scientific, Pittsburgh, PA, USA) and placed in a 60�C oven for about 2 hours. 
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The sections were deparaffinized in xylene and rehydrated in graded alcohol. 
They were then rinsed for 15 minutes in phosphate buffered saline (PBS). The 
endogenous peroxidase activity was blocked by 0.1% H2O2 in methanol for 15 
minutes. After washing with PBS thrice for 15 minutes (5 minutes for each 
wash), the epitopes on the tissue sections which were somehow sealed or 
hidden during tissue processing were retrieved by microwaving the sections in 
lOmM citric acid buffer (pH 6.0，Appendix VHT) for 7 minutes just after the 
buffer started to boil. The slides were allowed to cool to room temperature 
and were then washed with PBS. The nonspecific serum binding sites were 
blocked with normal horse serum (150^il serum was diluted with 10ml PBS) 
for 45 minutes. Afterwards, excess serum was blotted from sections and 
primary antibody was applied. For p53 and bcl-2 immunohistochemistry, p53 
pantropic (Ab-6) monoclonal antibody at a dilution of 1:25 (CALBIOCHEM, 
MA, USA) and clone 124 mouse anti-human bcl-2 oncoprotein at a dilution 
of 1:20 (DAKO, Denmark) were applied respectively and incubated ovemight 
at 4°C. For the negative control experiment, the primary antibody was 
replaced by 1% BSA in PBS. After primary antibody incubation, the slides 
were then washed with PBS for 30 minutes. The sections were incubated with 
biotinylated horse anti-mouse antibody (1:200) for 45 minutes. 1% BSA in 
PBS was used for both primary and secondary antibody dilution. The sections 
were washed for 30 minutes in PBS. Subsequent procedures for amplification 
(ABC reagents interactions) and colour development were the same as those 
described in section 2.2.1. tnmunoreactivity of p53 and bcl-2 proteins was 
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quantified based on a 12-point weighted score which was the same as those 
mentioned in section 2.2.1. 
4.2.2 In situ terminal transferase-mediated dUTP nick end labelling 
(TUNEL) 
Occurrence of apoptosis in the ovarian tissue sections was detected by 
employing the In situ Apoptosis Detection Kit (Oncor, Gaithersburg, MD, 
USA). Serial sections were cut at 7p,m thick from paraffin blocks using a 
microtome and the sections were incubated in 60°C oven for half an hour. The 
tissue sections were deparaffinized in xylene and were hydrated through 
graded alcohol. The slides were then washed in PBS for 5 minutes twice. 
Afterwards, the endogenous peroxidase activity was blocked by 0.3% H2O2. 
The slides were further washed with PBS thrice (5 minutes for each wash). Li 
order to facilitate the detection of apoptotic bodies, the protein in the tissue 
sections were digested by Proteinase K (lO^ig/ml, BDH, Dorset, England) for 
2 minutes at room temperature. The slides were washed in PBS twice and 
Equlibration Buffer was applied onto the tissue sections for 15 seconds. 
Excess buffer were blotted off and the tissue sections were incubated with TdT 
enzyme by mixing every 1 drop (32|il) of TdT Enzyme with 2 drops (76|oJ) of 
Reaction Buffer. The tissue sections were covered by plastic coverslips 
supplied along with the kit and the slides were placed in a prewarmed 
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humidified chamber. The slides were allowed to incubate in a 37°C incubator 
for 1 hour. For the negative control, distilled water was applied instead of the 
TdT enzyme. After 1 hour incubation, the enzymatic reaction was stopped by 
washing the slides with StopAVash Buffer at 37°C for 30 minutes with every 
10-minute agitation. The slides were then washed with PBS and were 
incubated with Anti-Digoxigenin Peroxidase for 30 minutes at room 
temperature in a humidified chamber. The slides were further washed with 
PBS and subsequently washed with 0.05M Tris Buffer. Six |Lll of 30% H2O2 
was added to 30 ml of 0.05% DAB solution and was immediately applied onto 
the sections for 5 minutes for color development. The slides were 
subsequently washed with Tris Buffer, counterstained with hematoxylin, 
dehyrated through graded alcohol, cleared with xylene and mounted with 
Permount. 
Quantitation of apoptosis was based on apoptotic index which 
represented the percentage of apoptotic epithelial cells in each tissue sample. 
A total of 10 fields from each tissue section were randomly chosen, and 100 
epithelial cells from each field were counted. For each sample, 5 sections 
were randomly selected for cell count. 
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4.3. Results 
4.3.1 Expression of p53 and bcl-2 in human ovarian tissues 
To study the expression of p53 and bcl-2 protein in ovarian tissues, a total 
of 112 paraffin-embedded tissues including normal ovaries, benign, borderline 
and invasive ovarian tumors were employed and 5-7 tissue sections from each 
specimen were cut and stained for immunoreactivity using a p53 pantropic 
(Ab-6) monoclonal antibody and monoclonal mouse anti-human bcl-2 
oncoprotein respectively. A 12-point weighted score was obtained based on 
both the intensity and the percentage of immunopositive cells. For the 
negative control where the primary antibody was replaced by l%BSA in PBS, 
neither the epithelial cells nor stroma showed any immunopositivity. 
Results on p53 immunohistochemical staining showed that the cellular 
location of the staining was found exclusively in nuclei of all immunopositive 
epithelial cells and that the staining appeared dark to light brown in color, p53 
expression was found in epithelial cells of 6 of 14 (43%) normal ovaries, 2 of 
7 ( 29%) benign ovarian tumors, and 5 of 29 (17%) borderline ovarian tumors. 
However, the weighted score for p53 among normal ovaries, benign and 
borderline tumors were around 0-2，indicating both the percentage of positive 
cells and the staining intensity of p53 expression in individual tissues were 
low. Lideed, over-expression of p53 protein was rare in normal ovaries (Fig. 
14A), benign (Fig. 14B) and borderline ovarian tumors (Fig. 14C). Jn 
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contrast, p53 expression was found in most of the invasive ovarian tumors 
(36/62, 58%), and most frequently found in high grade tumors, i.e. grade H 
(9/12, 75%) and grade m (20/29, 70%) than in low grade tumors, i.e. grade I 
tumors (7/21, 33%). Li grade HI tumors, for example, among those with p53 
immunopositive signals, 70% (14/20) of the tumors were score 12. 
Lrmiunohistochemical staining of p53 expression in invasive tumors was 
found exclusively in nuclei of epithelial cells but not in the underlying stroma. 
p53 immunopositive signals were shown in the nuclei of the epithelial cells 
invaded into the stroma (Fig. 15A-C) with no positive signals found in the 
stroma. 
For bcl-2 immunohistochemistry, the cellular location of the staining, 
unlike p53 staining which was localized in nuclei, was found in cytoplasm of 
epithelial cells and appeared light brown in colour. For normal ovarian 
surface epithelium with squamous epithelial cells, bcl-2 was expressed in the 
cytoplasm (Fig. 16A). bcl-2 was also found in the cuboidal epithelial cells of 
benign tumors (Fig. 16B) and columnar epithelial cells of borderline tumors 
(Fig. 16C). bcl-2 expression was frequently seen in normal ovaries (11/14， 
79%)，benign (7/7，100%) and borderline (13/18,72%) ovarian tumors. 
Among them the benign ovarian tumors showed the highest weighted score: 5 
of 7 (71%) specimen with weighted score of 10 or above). Whereas in the 
invasive ovarian tumors, there was a gradual reduction in the number of 
tumors which showed positive cells from grade I invasive tumors (6/20, 30%), 
to grade E invasive tumors (0/8，0%), and then to grade m invasive tumors 
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(0/15, 0%). Although grade I tumors showed a generally decreased in bcl-2 
expression compared with those of normal ovaries, benign and borderline 
tumors, expression could also be found in a grade I invasive tumors of 
endometrioid histological subtype (Fig. 17A) which was the only one sample 
among the invasive tumors that showed such a strong expression, bcl-2 
protein expression was absent in all of the grade H (Fig. 17B) and HI (Fig. 
17C) invasive tumors examined. 
The distribution of p53 and bcl-2 expression in normal ovaries and 
various ovarian tumors (Graph 6 and 7，respectively) showed that normal 
ovaries and benign ovarian tumors demonstrated frequent bcl-2 expression but 
rare p53 over-expression. On the other hand, invasive tumors (particularly 
grade H and grade EI tumors) over-expressed p53 protein but did not show any 
bcl-2 expression. Borderline tumors showed relatively higher bcl-2 expression 
and lower p53 over-expression, while grade I invasive tumors showed 
relatively lower bcl-2 expression and higher p53 over-expression. Jn addition, 
the graph (Graph 8) demonstrating the average weighted scores for those 
normal ovaries and various ovarian tumors which expressed bcl-2 andA)r p53 
proteins showed clearly two trends: i) an increase bcl-2 expression from 
normal ovaries to benign tumors, followed by a general decrease of bcl-2 
expression from benign tumors to invasive tumors; ii) a slightly increase in 
p53 over-expression from normal ovaries to borderline tumors, followed by a 
sharp elevations of p53 expression from borderline to invasive tumors. To 
investigate whether p53 and bcl-2 expression in normal ovaries and various 
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ovarian tumors showed an inverse correlation, Pearson Product Moment 
Correlation was made for estimating the correlation between different ovarian 
tissues. Results showed that there was no significant relationship between p53 
and bcl-2 expression in normal ovaries，benign tumors and borderline tumors. 
However, p53 and bcl-2 expression demonstrated a significant inverse 
correlation (r:-0.51626, P = 0.00295) in invasive ovarian tumors, indicating 
that invasive tumor specimens with bcl-2 expression showed no p53 over-
expression or vice versa), ln addition, a grade I tumors where both p53 and 
bcl-2 proteins were expressed was observed. When the grade I tumor was 
examined more closely, it was found that the squamous surface epithelial cells 
which expressed bcl-2 did not show p53 expression (Fig. 18A) while the 
epithelial cells expressing p53 in the stroma did not show bcl-2 expression 
(Fig. 18B). Thus even within the same tumor, the p53 and bcl-2 expression 
are mutually exclusive and both could not be found simultaneously in the same 
cell. 
4.3.2 Apoptosis in human ovarian tissues 
To investigate the occurrence of apoptosis in normal ovaries and various 
ovarian tumors, 103 paraffin-embedded ovarian tissues were sectioned and 
apoptotic epithelial cells in ovarian tissues were detected by in situ terminal 
transferase-mediated dUTP nick end labeling (TUNEL) method. Apoptotic 
epithelial cells were identified by dark brown staining of cells with 
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morphological characteristics: (1) isolated rather than patches of apoptotic 
epithelial cells (2) compaction of chromatin and (3) margination of nuclei etc.) 
(Fig 19 A-C). Negative control was performed using PBS instead of the 
enzyme TdT. Apoptosis was quantified by measuring the apoptotic index 
which represented the percentage of apoptotic epithelial cells in the tissue 
sections. 
The Graph 9 illustrated the distribution of the occurrence of apoptotic 
epithelial cells in different ovarian tissues. In generally, the number of 
apoptotic cells detected by in situ TUNEL method was low. However, among 
different ovarian tissues and even within different histological subtypes of 
invasive ovarian tumors, the apoptotic indices varied considerably. Despite 
variation of the apoptotic indices found in different ovarian tissues, the 
majority of the specimens with higher apoptotic indices (over 1.0) belonged to 
the borderline and invasive tumors. For all the invasive ovarian tumors 
examined, higher tumor grade was associated with a higher apoptotic index, 
with highest apoptotic indices mainly concentrated in grade EI invasive 
ovarian tumors while lowest in grade I tumors, grade H tumors being the 
intermediate. Li addition, higher apoptotic indices were found in serous 
tumors rather than mucinous tumors. For 7 mucinous ovarian carcinomas 
studied, 5 of them (71%) had no apoptotic epithelial cells found. Apoptotic 
index was significantly lower in normal ovaries (0-0.7) and benign ovarian 
tumors (0-0.4)，and most of them had even no apoptotic epithelial cells 
detected. 
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There is considerable evidence to show that the loss of apoptosis (e,g, 
p53-mediated apoptosis) is a critical event in tumorigenesis. ln fact, it appears 
that evasion of cell deletion via apoptotic cell death may be a requisite event in 
the development of malignant neoplasms (McDonnell, 1993). For example, 
several different DNA tumor viruses express protein products which inactivate 
the functions of both Rb and p53 proteins in order to allow tumor growth. 
Liactivation of Rb by expression of certain viral gene products (such as Ela, 
HPV E7, or a truncated SV40T antigen) which bind to Rb in mammalian cells 
appears to inhibit cell proliferation but enhance apoptotic tendencies. On the 
other hand, inactivation of p53 by other viral gene products, either interfering 
with p53 transcriptional activity (adenovirus Elb, or full length SV40T 
antigen), or targeting p53 proteolytic degradation (HPV E6) (reviewed by 
Kastan et al., 1995)，presumably inhibit apoptosis induced by the Rb binding 
proteins mentioned above. These may explain why many tumor viruses 
inactivate both Rb and p53. Further evidence suggested the role of apoptosis 
in the tumorigenesis using transgenic mouse model. Symonds et al. (1994) 
generated transgenic mice expressing a truncated form of SV40T antigen 
which bound to Rb but not to p53. The transgene targeted on the choroid 
plexus epithelium, enhanced apoptosis in the epithelial cells was noted. When 
this transgene was expressed in a p53-deficient mice, the apoptosis of the 
choroid plexus epithelial cells disappeared and tumors rapidly developed. 
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tapairment of apoptosis both in vitro and in vivo, resulting in 
predisposition to oncogenesis, has been most clearly shown for the proto-
oncogene bcl-2 (Reed et al., 1988). Over-expression of bcl-2 gene has been 
implicated in the pathogenesis of follicular B-cell lymphomas by protecting 
cells from apoptosis (Hockenbery et al., 1990). Li addition, high levels and 
aberrant pattems of bcl-2 gene expression have been reported in a wide variety 
of human cancers (reviewed by Reed et al., 1996). Another member of bcl-2 
gene family, bax gene, was shown to promote apoptosis (Oltvai et al., 1993) 
and was transactivated by p53. A marked decrease in the bax expression was 
shown without p53 function (Krajewski et al., 1995). However, little is known 
about the importance of apoptosis and its regulation in epithelial ovarian 
cancer. Therefore the expression of apoptosis-regulatory proteins, p53 and bcl-
2, in normal ovarian surface epithelium and various ovarian epithelial tumors 
were examined in this report. Besides, the occurrence of apoptosis in various 
ovarian tissues was also investigated. 
An immunohistochemical method was used to examine the expression of 
p53 protein and expression of bcl-2 protein in normal ovarian surface 
epithelium and epithelial cells of benign, borderline and invasive ovarian 
tumors. The results showed that expression of p53 was exclusively found in 
invasive ovarian tumors and absent in normal ovaries, benign and borderline 
ovarian tumors. Such result was consistent with previous studies that p53 
over-expression was a common event in invasive or malignant ovarian tumors 
but was rare in normal ovaries, benign and borderline ovarian tumors (Diebold 
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et al., 1996; Berchuck et al., 1994). Kyprjanczik et al. (1993) also estimated 
that around 80% of mutations found in ovarian cancers are associated with an 
over-expression of p53 protein. Mutations leading to p53 over-expression 
appeared to be important in the development of invasive ovarian tumors, but 
not benign and borderline tumors. Since the half-life of wild-type p53 protein 
is rather short compared to the stable mutant p53 protein, the expression of 
wild-type p53 protein in normal ovarian surface epithelial cells cannot not be 
detected. Jf ovarian carcinogenesis involves orderly progression from a benign 
or borderline to early then advanced invasive ovarian tumors, then a gradual 
increase in p53 expression from benign to malignant tumors should be 
observed. Since such a gradual increase in the expression of p53 in ovarian 
tumors was not observed in this studied and have other previous studies, it 
was suggested that p53 mutation or over-expression was an important step 
only in the development of invasive ovarian carcinogenesis. Rather than 
representing benign forms of invasive tumors, benign and borderline tumors 
may be distinct entities that arise as a result of the molecular genetic 
alterations different from those found in invasive tumors. Among the invasive 
ovarian tumors, p53 over-expression was more frequently seen in higher 
graded tumors than in lower graded tumors, and thus as the expression levels 
of p53 protein became higher, the epithelial tumor cells became less organized 
i.e. more undifferentiated. 
feterestingly, the expression pattem of bcl-2 protein appeared to change 
in an opposite direction of that of p53 expression. Immunohistochemical 
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studied revealed that bcl-2 expression was more frequently observed in normal 
ovarian surface epithelial cells, benign and borderline epithelial tumors. Jn 
contrast, the bcl-2 expression was down-regulated in invasive ovarian 
epithelial tumors. Even among the invasive ovarian tumors, bcl-2 expression 
was detected in grade I tumors but was absent in almost all the grade H and HI 
invasive tumors. Such findings were different from the results for p53 where 
p53 over-expression was exclusively seen in invasive tumors. Although 
similar observations were reported by Diebold et al. (1996)，the present study 
showed a clear comparison between bcl-2 expression and p53 expression 
among different types of ovarian tissues. An inverse correlation (r:-0.51626, 
P = 0.00295) was found between bcl-2 and p53 expression during ovarian 
carcinogenesis. Results also indicated that only one grade I invasive ovarian 
tumor expressed both bcl-2 and p53 protein, while all other ovarian tissues 
demonstrated a mutually exclusive expression pattem between p53 and bcl-2. 
Evidence for the inverse relationship became stronger on further examination 
of the grade I tumor which expressed both proteins. The grade I tumor showed 
invasion of epithelial cells into underlying stroma. The invading epithelial 
cells, like the epithelial cells of other invasive tumors (particularly grade H and 
n i invasive tumors), showed strong p53 expression, whereas some of the 
epithelial cells still remained as squamous epithelial cells on the surface of the 
ovary without invading into the stroma had no p53 expression. Jn contrast, the 
non-invading epithelial cells that maintained the normal phenotypic 
appearance expressed bcl-2 expression, bcl-2 expression was not found in the 
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invading epithelial cells or cells with p53 expression. This observation clearly 
demonstrated that p53 and bcl-2 expression showed an inverse correlation with 
each other during ovarian carcinogenesis. 
Miyashita et al. (1994) identified a p53-regulatory domain present in the 
5 ‘ untranslated region of bcl-2 gene which can inhibited bcl-2 expression. 
Moreover, Haldar et al. (1994) showed that over-expression of mutant p53 in 
breast cancer cell line (MCF-7) could induce down-regulation of the bcl-2 both 
at protein and mRNA levels. Since, the antibody used in our study can detect 
both wild-type and mutant p53 protein, the findings obtained in the present 
study are consistent with the hypothesis that both wild-type and mutant p53 
protein are able to down-regulate bcl-2 expression. Our results also suggested 
that bcl-2 have important in physiological function in normal ovary, in which 
bcl-2 may confer survival advantages in the normal ovarian surface epithelial 
cells when the cells are subjected to the damage during ovulation. Down-
regulation of bcl-2 expression may thus disrupt the normal physiological 
function of the normal ovary, eventually leading to the development of ovarian 
neoplasms in some cases. Down-regulation of bcl-2 expression may also be 
result of the inhibitory effect of p53 over-expression on bcl-2 during ovarian 
carcinogenesis. However, no previous studies had been reported on the effect 
of bcl-2 removal (knock-out) in immortalized human surface ovarian epithelial 
(HOSE) cell line, or on the transfection of bcl-2 into ovarian carcinoma cell 
line. Whether or not bcl-2 down-regulation itself was a main cause or just a 
secondary effect during ovarian carcinogenesis remains to be elucidated. 
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Apoptosis was analyzed by in situ terminal transferase-mediated dUTP 
nick end labelling (TUNEL) method and quantification of apoptosis was based 
upon the measurement of the apoptotic index. The results shown that 
apoptotic cells were observed to scatter among the normal surface epithelial 
cells. The apoptotic cells were frequently found in grade H and especially in 
grade HI invasive tumors, as indicated by the high apoptotic indices. Normal 
and benign type ovarian epithelial cells had low apoptotic indices, reflecting 
apoptosis rarely occurred in these two types of ovarian tissues. Grade I 
invasive tumors and borderline ovarian tumors showed an intermediate level 
of apoptotic index. However, such observations appeared to have no 
association with the expression of bcl-2 and p53 protein. 
Most of the previous studies had focused on the effects of bcl-2 or its 
gene family and/or p53 on the modulation of apoptosis in the development of 
cancers in different tissues. Sinicrope et al. (1995) examined whether bcl-2 
expression is activated during colorectal tumorigenesis and its relationship to 
p53 expression. They also examined the association of p53 and bcl-2 
expressions with spontaneous apoptotic rates in epithelial cancers. They found 
an inverse correlation between bcl-2 and p53 expression in colorectal 
adenomas, suggesting that these markers may regulate a common cell death 
pathway. Furthermore, carcinomas with a high percentage of bcl-2 positive 
cells were significantly more likely to have low rates of spontaneous apoptosis. 
Ofner et al. (1995) also found that bcl-2 protein appeared to be associated with 
favorable clinical outcome, decreasing lymphocytic infiltration and reduced 
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tumor size. On the other hand, Marin et al, (1994) used bcl-2-lg, p53 
�knockout ‘ (p53KO) and p53 KCVbcl-2 hybrid mice to demonstrate the role 
of bcl-2 and p53 in in vivo lymphogenesis. They found that over-expressed 
bcl-2 suppressed wild-type p53-dependent apoptosis following y-radiation, 
indicating that bcl-2 and p53 serve a suppressor and effector function, 
respectively, in a common cell death pathway. Miyashita et al. (1994b) also 
demonstrated that transfection of a temperature sensitive p53 mutant down-
regulated bcl-2 expression, and simultaneously up-regulated bax gene 
expression in the murine leukemia cell Ml. Furthermore, 0 ‘ Neil et al. (1996) 
found that bcl-2 expression and p53 over-expression were not correlated with 
attenuated apoptosis in non-small lung carcinoma. 
Our results suggested that apoptosis during ovarian carcinogenesis 
occurred either independently to, or not directly modulated by, bcl-2 and p53 
expression. It was likely that the effects on apoptosis of bcl-2 and p53 were 
modulated by other gene products that regulated apoptosis in vivo. 
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To sum up, the present study on DOC-2 gene, which was shown to be a 
differentially expressed gene in human ovarian cancer, demonstrated that (1) 
the expression of DOC-2 protein was expressed in normal ovaries, benign and 
borderline ovarian tumors, but down-regulated in the invasive ovarian tumors; 
(2) down-regulation of DOC-2 protein was rare in invasive tumors of 
mucinous histological subtypes; (3) transfection of DOC-2 gene into human 
ovarian carcinoma cell line showed a reduced growth rate in an in vitro culture 
system; (4) inoculation of DOC-2 transfected ovarian carcinoma cell line into 
athymic nude mice was not able to induce the formation of tumors. All these 
evidence supports the notion that DOC-2 functions as a tumor suppressor. 
Several pieces of evidence, including the presence of phosphotyrosine 
interaction domain and interactions with TGF_P, suggested that DOC-2 may 
involve in signal transduction. Li addition, DOC-2 gene shares a conserved 
sequence with some genes that involve in embryonic development. Li the 
present study, DOC-2 protein was expressed in a number of embryonic tissues 
such as cartilage, brain, kidney, etc. and the expression increased with 
embryonic age. DOC-2 was expressed in embryonic kidneys but not in adult 
kidneys. In vitro kidney culture demonstrated that depletion of DOC-2 gene 
product affect the growth of kidneys. 
iicreasing evidence suggested that apoptosis, a genetically controlled cell 
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death programme, may play a role in human carcinogenesis. Li this report, two 
proteins, p53 and bcl-2, which was well known of their involvement in 
apoptosis, were shown to have inverse correlation in their expression in human 
invasive ovarian tumors. However, results revealed that expression of p53 and 
bcl-2 may not directly modulate apoptosis during the ovarian carcinogenesis. 
Further experiments can be followed based on the present studies, i i 
order to know more about the physiological function of DOC-2 gene, DOC-2 
knockout mice where the DOC-2 gene is removed from normal expression 
should be developed to see if there is any abnormality observed. Focus should 
be given these abnormal structures of the knockout mice to establish whether 
there are any concomitant defects along the signal transduction pathway of 
DOC-2 gene. On the other hand, a detailed mRNA expression pattem during 
mouse embryonic development should also be established. In addition, the 
effect of DOC-2 gene in embryonic kidney development can be further 
analyzed by culturing the embryonic kidneys at different stages and then the 
DOC-2 expression is blocked by addition of either DOC-2 antibody or DOC-2 
antisense RNA. Total protein, DNA content and both the mRNA and protein 
expressions of the treated kidneys can also be followed. 
Li the present study, bcl-2 was shown to be down-regulated in invasive 
ovarian tumors by immunohistochemical method. However, such method did 
not provide information on how down-regulation can lead to tumor formation. 
Therefore, the transfection of bcl-2 cDNA into ovarian carcinoma cell line can 
be performed to examine whether bcl-2 have any direct role to play during the 
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development of ovarian cancer. Furthermore whether bcl-2 would interact 
with its gene family member i.e. bax, in the development of ovarian cancer is 
also worth to study. On the other hand the expression pattem of bcl-2 was 
similar to that of DOC-2 gene in different ovarian tissues. Whether there are 
any relationships or interaction among DOC-2, p53 and bcl-2 proteins remains 
to be elucidated. 
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Appendix I 
Preparation of Phosphate Buffered Saline (PBS) 
1. To 800ml double distilled, add 1.5 g sodium hydrogen phosphate 
(Na2HPO4), 8 g sodium chloride (NaCl), 0.2 g potassium chloride (KC1) 
and 0.2 g potassium hydrogen phosphate (KH2PO4). 
2. Stir until all the salts are dissolved. 
3. Adjust the pH to 7.2-7.4 with l N NaOH or l N HC1, and then make up the 
volume into 1 litre. The buffer is now ready for use. 
Appendix II 
Preparation of0.05M Tris Buffer 
1. To 800 ml double distilled water, add 6.1 g Triza base and stir. 
2. When the powder has completely dissolved, adjust the pH to 7.2. 
3. Make up the buffer solution to 1 litre by adding double distilled water. The 
buffer solution is now ready for use. 
• — — 
Appendix III 
Preparation of M199 Medium 
1. Pour one bottle of M199 powder into 800 ml of sterilized Mill i-Q water 
and stir gently. 
2. When the powder has completely dissolved, add 2.2 g sodium bicarbonate 
(NaHCO3). 
3. After the solution has become clear, adjust the pH with 1 N NaOH or 1 N 
HC1 to 7.1 - 7.2 because the pH wil l normally rise 0.1 to 0.3 units during 
filtration. 
4. Add Milli-Q water to bring medium to 1 litre. 
5. Sterilize medium by filtering through a 0.2 [im membrane. 
6. Dispense the medium into four 250 ml bottles, and kept at 4° C for a 
maximum period of 3 months. 
! U2 
Appendix IV 
Preparation ofMCDB-105 Medium 
1 • To a 800 ml sterilized Mil l i-Q water, add a bottle of MCDB-105 powder. 
2. Stir until all chemicals have dissolved, then adjust the mixture with l N 
NaOH or l N HC1 to pH 7.35 - 7.45. 
3. Add more water to bring the medium to 1 litre. 
4. Filtered the medium through a membrane with a porosity of 0.2 ^m. 
5. Dispense the medium into four 250 ml bottles, and then kept at 4° C for 
not more than 3 months. 
； f33 
Appendix V 
Preparation of Hank's Balanced Salt Solution (HBSS) 
1. Pour one pack of Hank's Balanced Salt Solution powder into 800 ml of 
sterilized Mil i-Q water and stir gently. 
2. After all the powder has completely dissolved, add 0.35g sodium 
bicarbonate. 
3. When the sodium bicarbonate powder have dissolved, adjust the pH with 
l N NaOH or l N HC1 to 7.2 - 7.3 
4. Add Mil i-Q water to adjust the volume to llitre. 
5. Sterilize the Hank's solution by filtering through a 0.2 ^m membrane. 
6. Dispense the Hank's solution into four 250 ml bottles, and kept at 4°C for 
a maximum period of 3 months. 
； l34 
Appendix VI 
Preparation of Dulbecco，s ModiHed Eagle Medium: Nutrient Mixture F-
12 (Ham) (D-MEM/F-12,1:1) 
1. Dissolve a pack of (D-MEM>^-12, 1:1) in 800 ml Mil i-Q water and stir 
gently. 
2. When the medium bacome clear, add 3.2 g sodium bicarbonate to the 
medium and stir gently. 
3. After the sodium carbonate has been dissolved, adjust the pH to 7.4 with 
l N HC1 or l N NaOH. 
4. Make up the volume to 1 litre by adding Mili-Q water. 
5. Sterilize the medium by filtering through membrane with a pore size of 0.2 
^im. 
6. Dispense the medium into four 250 ml bottles and kept at 4°C for not more 
than 3 months. 
• f35 
Appendix VII 
Preparation ofL-EIBOVITZ 's L-15 MEDIUM (L-15 medium) 
1. Dissolve a pack of L-EffiOVITZ's L-15 MEDRJM (L-15 medium) in 800 
ml Mil i-Q water and stir gently. 
2. After the medium become clear, adjust the pH to 7.4 with l N HC1 or l N 
NaOH. 
3. Make up the volume to 1 litre by adding Mili-Q water. 
4. Sterilize the medium by filtering through membrane with a pore size of 0.2 
\im. 
5. Dispense the medium into four 250 ml bottles and kept at 4°C for not more 
than 3 months. 
• — 
Appendix VIII 
Preparation ofO.OlM Citric Buffer 
1. Add 3.82 g citric acid and 2.412 g sodium citrate into 800 ml double 
distilled water. 
2. Stir until all the powder has dissolved. 
3. Adjust pH with l N HC1 or l N NaOH to 6.0 
4. Add double distilled water to make up the final volume to 1 litre. 
5. Dispense the medium into four 250 ml bottles and kept at 4°C for not more 
than 3 months. 
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Fig. 1: Western analysis of DOC-2 protein expression in 
transfected cell lines. 
GAP (GTPase-activating protein) was act as a 
loading control. 
Fig. 2A: Photomicrograph of a section taken from a normal ovary and stained 
with the DOC-2 antibody. Al l the normal, squamous ovarian epithelial 
cells (E) shown was found to be immunoreactive to the antibody and 
was stained brown in color, while the underlying stroma (S) did not 
show any staining. L:nmunoreactive signals were localized in the 
cytoplasm of the epithelial cells. Counterstained with hematoxylin, 7jxm 
thick, bar = 50^im. 
Fig. 2B: Photomicrograph of a section taken from a benign ovarian tumor and 
stained with the DOC-2 antibody. The epithelial cells (E) appeared 
cuboidal in shape, tomunoreactive signals were found in cytoplasm of 
the epithelial cells. The underlying stroma (S) showed negative 
staining. Counterstained with hematoxylin, 7^m thick, bar = 50p,m. 
Fig. 2C: Photomicrograph of a section taken from a borderline ovarian tumor 
and stained with the DOC-2 antibody. The epithelial cells (E) were 
either cuboidal or columnar in shape. Some of the epithelial cells no 
longer monolayered but demonstrated multilayering. Brown 
immunoreactive products were found in the cytoplasm of epithelial cells 
while the stroma (S) did not show positive immunoreactivity. 
Counterstained with hematoxylin, 7p,m thick, bar = 50^im. 
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Fig. 3A: Photomicrograph of a section taken from a grade I serous invasive tumor 
and stained with the DOC-2 antibody. The epithelial cells (E) showed 
multilayering and papillary structures. The pale brown positive staining 
was also found in the cytoplasm of epithelial cells of the grade I tumor, 
but both staining intensity and numbers of positive cells were relatively 
lower than those found in normal ovaries and benign and borderline 
tumors. Stroma did not show positive staining. Counterstained with 
hematoxylin, 7^im thick, bar = 50p,m. 
Fig. 3B: Photomicrograph of a section taken from a grade DI serous invasive 
tumor and stained with the DOC-2 antibody. The poorly differentiated 
epithelial cells (E) had invaded into the stroma, tamunoreactive 
staining was not found in any of the grade EI tumors examined. 
Counterstained with hematoxylin, 7^im thick, bar = 50jim. 
Fig. 3C: Photomicrograph of a section taken from a borderline tumor for negative 
control. The DOC-2 antibody was replaced by 1% BSA in PBS. Both 
epithelial cells (E) and the stroma (S) showed no immunopositive 
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Fig. 4A: Photomicrograph of a section taken from a grade I invasive tumor of 
mucinous subtypes and stained with the DOC-2 antibody. The 
mucinous tumor was lined by the tall columnar epithelium with nuclei 
at the basal side. The mucinous tumor showed strong immunostaining 
signals in the cytoplasm of epithelial cells (E). The stroma (S) dids not 
show positive signal. Counterstained with hematoxylin, 7p,m thick, 
bar = 50^m. 
Fig. 4B: Photomicrograph of a section taken from a grade H invasive tumor of 
mucinous subtypes and stained with the DOC-2 antibody. The grade E 
mucinous tumor also showed strong immunostaining signals in the 
cytoplasm of epithelial cells (E). Goblet cells (G) which were 
characteristic of mucinous tumors were frequently found. The stroma 
(S) dids not show positive signal. Counterstained with hematoxylin, 
l\xm thick, bar = 50pm 
Fig. 4C: Photomicrograph of a section taken from a grade I mucinous invasive 
tumor for negative control and stained with the preadsorbed DOC-2 
antibody. The DOC-2 antibody was preadsorbed with the synthetic 
peptide unique to DOC-2 protein, before incubated with the tissue 
section. Both epithelial cells and the stroma showed negative 
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Fig. 5A-D: Phase contrast photomicrograph of the SKOV3 transfectant cell lines 
taken when cells reached 80% confluency. Fig. 5A and 5B showed 
the SKNEO-1 and SKNEO-2 cell lines respectively, which were the 
SKOV3 cell line transfected with the vector only. The cells were 
ovoid in shape. Fig. 5C showed the SKDOC-2-36 cell line which 
was the SKOV3 cell line transfected with DOC-2 gene. 
Morphologically, they did not show obvious difference from the neo 
transfected cell lines. Fig. 5D showed the SKDOC-2-43 cell line 
which was also transfected with DOC-2. SKDOC-2-43 cell line 
showed an obvious difference from the other three cell lines by its 
flattened and polygonal appearance, with granular deposits inside the 
nuclei. Bar = 50 ^m. 
_ j 4 j “ “ 
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Fig. 6: Photomicrograph of a frozen section taken from the urogenital ridge of a 
11 d.p.c. ICR mouse embryo and stained with the DOC-2 antibody. 
Weak immunopositive signals were found in the cytoplasm of the 
epithelial cells of the mesonephric ducts (MD). Counterstained with 
hematoxylin, 8 |LUn thick, bar = 50^im. 
Fig. 7: Photomicrograph of a paraffin section taken from a 14 d.p.c. ICR mouse 
embryo and stained with the DOC-2 antibody. Clear immunoreactivity 
was found in the periphery of chondrocytes of the Meckel's cartilage. 
Counterstained with hematoxylin, 7 p,m thick, bar = 50^m. 
































































































































































































Fig. 8A: Photomicrograph of a frozen section taken from the brain of a 14 d.p.c. 
ICR mouse embryo and stained with the DOC-2 antibody. The brown 
immunoreaction products were found in the nerve fibers (NF) among 
neuronal cells. The neuronal cell bodies did not show immunopositive 
signal. Counterstained with hematoxylin, 8 \im thick, bar = 50p:n. 
Fig. 8B: Photomicrograph of a frozen section taken from the brain of a 17 d.p.c. 
ICR mouse embryo and stained with the DOC-2 antibody. The brown 
reaction products of immunohistochemistry were found in the nerve 
fibers. No immunopositive signal was observed inside the neuronal cell 
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Fig. 9A: Photomicrograph of a paraffin section taken from the hippocampus of 
an adult brain and stained with the DOC-2 antibody. The 
immunopositive cells were found in the dentate gyrus (DG) and part of 
CA3 of the hippocampus. Regions in hippocampus other than these 
area did not show DOC-2 immunostaining. Counterstained with 
hematoxylin, 7 \im thick, bar = 200p,m. 
Fig.9B: Higher magnification of the positive cells in Fig. 9A. Strong 
immunopositive signals were found inside the nuclei of the pyramidal 
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Fig. lOA: Photomicrograph of a frozen section taken from the kidney of a 15 
d.p.c. ICR mouse embryo and stained with the DOC-2 antibody. 
Brown color (arrow) was found in the medulla of the embryonic 
kidney. Counterstained with hematoxylin, 8 \im thick, bar = 200^m. 
Fig. lOB: Higher magnification of the positive region in Fig. lOA. DOC-2 
immunopositive signal was found in the metanephric tubules (arrow). 
Structures other than the metanephric tubules did not show positive 
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Fig. l l A - D : Phase contrast photomicrograph of 13.5 d.p.c. embryonic kidneys 
in the organ culture. Fig. 11A and B showed the embryonic 
kidneys on day 1，which was the day the antibody was added. Fig. 
1 l A showed the control kidney without antibody treatment, while 
Fig. 11B showed the kidney treated with the antibody. No 
significant change in size was observed. On day 2，difference in 
size between the two groups of kidneys was observed. Fig. 11C 
showed the control kidney on day 2, and the kidney was larger 
than the kidney on day 1 shown in Fig. 1 lA . Fig. 1 l D showed the 
antibody-treated kidney on day 2 and the size of the kidney was 
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Fig. 12 A-B: Phase contrast photomicrograph of 13.5 d.p.c. embryonic kidneys 
on day 4 of the organ culture. Fig. 12A showed a control kidney 
on day 4. The size of the kidney on day 4 was shown to be larger 
than that on day 1 (Fig. l lA ) . Fig. 12B showed an antibody-
treated kidney on day 4. The size of the kidney was significantly 
smaller than the control counterpart shown on Fig. 12A. Bar = 
0.5mm. 
Fig. 12C-D: Phase contrast photomicrograph of 13.5 d.p.c. embryonic kidneys 
on day 5 of the organ culture. Fig. 12C and Fig. 12D showed the 
control and the antibody-treated kidney grown in vitro on day 5. 
The size of the control kidney was two-fold larger than that of the 
antibody-treated kidney. Bar = 0.25mm. 
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Fig. 13A-B: Photomicrograph of a frozen sections taken from the antibody-
treated kidney and stained with hematoxylin and eosin. Fig. 13A 
showed a section taken near the surface of the antibody-treated 
kidney. Kidney tubules (T) was found in the section. Fig. 13B 
showed a section taken from a more central part of the antibody-
treated kidney. Glomeruli which were not frequently seen in the 
peripheral part of the kidney, were shown in this section. The 
antibody-treated kidney was appeared histologically normal. Bar = 
lOO^im. 
Fig. 13C: Photomicrograph of a frozen section taken from the control kidney 
and stained with hematoxylin and eosin. Glomeruli (G) and 
kidney tubules (T) were also found in the control kidney. Bar = 
100|Lun. 
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Fig. 14A: Photomicrograph of a section taken from a normal ovary and stained 
with the p53 monoclonal antibody. The squamous ovarian epithelial 
cells (E) and the underlying stroma (S) did not show any 
immunoreactivity. Counterstained with hematoxylin, 7m thick, bar = 
lOO^m. 
Fig. 14B: Photomicrograph of a section taken from a benign ovarian tumor and 
stained with the p53 monoclonal antibody. The squamous ovarian 
epithelial cells (E) and the underlying stroma (S) did not show any 
immunoreactivity. Counterstained with hematoxylin, 7m thick, bar = 
lOO^m. 
Fig. 14C: Photomicrograph of a section taken from a borderline ovarian tumor 
and stained with the p53 monoclonal antibody. The cuboidal ovarian 
epithelial cells (E) and the stroma (S) did not show any 
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Fig. 15A: Photomicrograph taken from a grade I invasive tumor of serous 
subtype and stained with the monoclonal p53 antibody. The 
epithelial cells (E) of the grade I tumor had already invaded into the 
stroma (S). Dark brown immunoreaction products were found inside 
the nuclei of the epithelial cells but not in the cytoplasm, 
tomunopositive signals were not observed in the stroma (S). 
Counterstained with hematoxylin, 7m thick, bar = lOO^m. 
Fig. 15B: Photomicrograph taken from a grade E invasive tumor of serous 
subtype and stained with the monoclonal p53 antibody. The 
epithelial cells (E) of the grade E tumor showed dark brown 
immunopositive signals exclusively in the nuclei of the epithelial 
cells while the stroma (S) did not show any p53 immunoreaction. 
Counterstained with hematoxylin, 7m thick, bar = lOO^im. 
Fig. 15C: Photomicrograph taken from a grade HI invasive tumor of serous 
subtype and stained with the monoclonal p53 antibody. The poorly 
differentiated epithelial cells (E) showed invasion into the stroma 
(S). p53 immunoreactivity was observed in the nuclei of the 
epithelial cells but not in the stroma of the tumor. Counterstained 
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Fig. 16A: Photomicrograph of a section taken from a normal ovary and stained 
with the monoclonal bcl-2 antibody. The squamous epithelial cells 
(E) showed immunopositive staining in the cytoplasm. The 
underlying stroma (S) of the normal ovary did not show positive 
staining. Counterstained with hematoxylin, 7m thick, bar = lOOjLUn. 
Fig. 16B: Photomicrograph of a section taken from a benign ovarian tumor and 
stained with the monoclonal bcl-2 antibody. The cuboidal or low 
columnar epithelial cells (E) showed strong bcl-2 positive staining in 
the cytoplasm. The underlying stroma (S) of the benign tumor 
showed either no or weak bcl-2 immunostaining. Counterstained with 
hematoxylin, 7m thick, bar = lOO^m. 
Fig.l6C: Photomicrograph of a section taken from a borderline ovarian tumor 
and stained with the monoclonal bcl-2 antibody. Papillary structures 
were frequently found in the borderline tumor. For bcl-2 
immunostaining, the cytoplasm of the epithelium (E) of the borderline 
tumor showed pale brown immunoreactive signal. The underlying 
stroma (S) did not show positive bcl-2 signal. Counterstained with 
hematoxylin, 7m thick, bar = lOO^m. 
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Fig. 17A: Photomicrograph of a section taken from an endometrioid subtype of 
the grade I invasive tumor and stained with the monoclonal bcl-2 
antibody. The endometrioid borderline tumor showed regular 
glandular appearance with tall columnar epithelium. The bcl-2 
immunoreactivity in the epithelial cells (E) was strong as 
demonstrated by the dark brown staining in the cytoplasm. The 
stroma did not show any brown products. Counterstained with 
hematoxylin, 7m thick, bar = lOOfim. 
Fig. 17B: Photomicrograph of a section taken from a grade H serous invasive 
tumor and stained with the monoclonal bcl-2 antibody. Epithelial 
cells, apart from lining on the surface of the stroma, were also found 
inside the stroma. The serous tumor showed no bcl-2 
immunoreactivity in both epithelial cells (E) and the underlying 
stroma (S). Counterstained with hematoxylin, 7m thick, bar = 
lOO^m. 
Fig. 17C: Photomicrograph of a section taken from a grade HI serous tumor and 
stained with the monoclonal bcl-2 antibody. Poorly differentiated 
epithelial cells (E) found inside the stroma (S) did not show any bcl-2 
expression. Counterstained with hematoxylin, 7m thick, bar = lOOp,m. 
— 
M^ ,  













































 1  -


































































































Fig 18A: Photomicrograph of a section taken from a grade I serous tumor and 
stained with the bcl-2 monoclonal antibody. Epithelial cells (NE) 
which were on the surface of the stroma and were of squamous 
appearance demonstrated brown immunopositive signal (arrow), 
whereas the epithelial cells which had already invaded into the stroma 
(EE) did not show bcl-2 immunoreactivity. Counterstained with 
hematoxylin, 7m thick, bar = lOO^m. 
Fig 18B: Photomicrograph of a section taken from the adjacent section shown 
in Fig. 18A and stained with the p53 monoclonal antibody. No p53 
immunopositive signals in epithelial cells (NE) with bcl-2 expression 
were observed. However, the invaded epithelial cells (正）that were 
inside the stroma showed strong p53 expression. Counterstained with 
hematoxylin, 7m thick, bar = 100|Lun. 
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Fig 19A-C: Photomicrographs taken from a borderline (Fig.l9A), a grade I 
serous invasive tumor (Fig. 19B), and a grade HI serous invasive 
tumor (Fig. 19C) and stained for the apoptosis by TUNEL. The 
apoptotic epithelial cells (arrow) found in the tissue sections shared 
the characteristics, such as the isolated epithelial cells stained brown 
in color and compaction and segregation of chromatin lying against 
the nuclear membrane. Counterstained with hematoxylin, 7m thick, 
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Table 1. Current FIGO Staging System for primary ovarian carcinoma 
Stage I Growth limited to the ovaries. 
Stage I I Growth involving one or both ovaries with pelvic extension. 
Stage I I I Tumor involving one or both ovaries with peritoneal implants outside the 
pelvis andA)r positive retroperitoneal or inguinal nodes. Superficial liver 
metastsis equals stage III. Tumor is limited to the true pelvis but with 
histologically verified malignant extension to small bowel or omentum. 
Stage IV Growth involving one or both ovaries with distant metastatsis. I f pleural 
effusion is present, there must be positive cytologic test results. 
*Data from International Federation of Gynecology and Obstetrics. Changes in definitions of 
clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156:246, 1987. 
Table 2. Expression of DOC-2 protein in human ovarian tissues 
Ovarian Specimen Sample Immunopositivity Mean Standard 
number (weighted score >0) weighted error 
n x/n (%)* score 
Normal “ 13 —12/13 ( 9 2 . 3 % ) ~ 3.80 1.09 — 
Benign 一 6 — 6/6 (100%) 6.85 1.07 — 
Borderline 16 — 12/16 (75%) 3.39 0.70 
Invasive Grade I “ 20 “ 8/20 (40%) 1.47" —0.65 
Invasive Grade II 8 — 2/8 (25%) 1.43^ 1.03 
Invasive Grade III 1^ 0/16 (0%) 0 0 ^ OTO~~ 
^^H^^^^^^^^^^^^^^^^^^^^^^^^^ H^^^^WMMnHMI^H^^^^^^^^^ W^HMMHM^^^^^^^^^^^^^^^^^MLMMMMMMHH^^^^^^^^^MiaiMH_^^^^^^^MMH^HH 
* n represents total number of tissues studied; x represents the number of tissues with weighted 
score > 0 
Number in parenthesis represents percentages of specimens which showed immunoreactivity. 
p < 0.05, by one way ANOVA (Dunn's test) ^ statistically significant difference vs normal 
b statistically significant difference vs benign 
e statistically significant difference vs borderline 
Table 3. Expression of DOC-2 protein in human ovarian tissues excluding 
all mucinous tissues 
Ovarian Specimen Sample Immunopositivity Mean Standard 
number (weighted score >0) weighted error 
n x/n (%)* score 
Normal 13 — 12/13 (92.3%) 3.80 1.09 
Benign 一 6 — 6/6 (100%) 6.85 1.07 
Borderline 14 — 11/14 (78.6%) 3.61 0.76 
Invasive Grade I “ 15 “ 3/15 (20%) 0.44 ^ ^^  — 0.26 
Invasive Grade II “ 6 0/6(0%) — 0.00"^^ 0.00 “ 
Invasive Grade III 16 0/16 (0%) 0.00"^^ 0.00 
* n represents total number of tissues studied; x represents the number of tissues with weighted 
score > 0 
Number in parenthesis represents percentages of specimens which showed immunoreactivity. 
p < 0.05，by one way ANOVA (Dunn's test) ^ statistically significant difference vs normal 
b statistically significant difference vs benign 
e statistically significant difference vs borderline 
Table 4. DOC-2 protein expression pattern in mouse embryos. 
embryonic stage (days postconception)* 
embryonic tissues 11 12 13 14 15 17 
mesonephric duct + ++ N.A. N.A. N.A. N.A. 
dorsal root - + + ++ ++ + + + “ 
ganglion 
s ^ : + + + + + + + + + + + ~ 
cartilage - - ++ +++ +++ + + + ~ 
primordium 
kidney — - - 一 - + ~ + + +++ 
brain — - “ - — - + ++ +++ 




N.A.: not applicable 
Table 5. Correlation between p53 and bcl-2 weighted score in normal 
ovaries and various ovarian tumors 
Sample number Pearson's correlation Confidence level 
(n) coefficient (r) (jp) 
“ N o r m a l ovaries f I -0.026 0.940 
~ B e n i g n tumors 7 -0.032 0.946 
Borderline tumors l3 “ -0.163 0.595 
*Invasive tumors Sl -0.516 0.003 
* sample showing significant inverse correlation between p53 and bcl-2 expression for 
individual sample comparison ¢) < 0.05，by Pearson Product Moment Correlation). 
Negative value ofPearson's correlation coefficient (r) indicates the inverse correlation. 
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Graph 1: DOC-2 weighted scores of normal ovaries and various ovarian 
tumors. Numbers in parenthesis represent sample numbers. 
Red solid symbols represent tumors of mucinous subtypes. 
*, numbers of tumor with 0 weighted score: 
borderline tumors: 4 
grade I invasive: 12 
grade I I invasive: 6 
grade EI invasive: 16 
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Graph 2: DOC-2 weighted scores for normal ovaries and various ovarian 
tumors excluding all the mucinous tumors. Numbers in parenthesis 
represent sample numbers. 
*, numbers of tumor with 0 weighted score: 
borderline tumors: 3 
grade I invasive: 12 
grade II invasive: 6 
grade III invasive: 16 
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Graph 3: Growth curve of transfected cell lines, **Cell line with a cell number 
significantly smaller (p < 0.05) than the cell numbers ofboth neo 
transfectants; *Cell line with a cell number significantly smaller 
(p < 0.05) than the cell numbers of one of the neo transfected cell lines. 
Error bars represent standard error of the mean. 
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Graph 4: The graph of the growth of xenografts in athymic nude mice after 
inoculation of tumor cells. Error bar represents standard error of 
the mean, *statistically different from the SKNEO-2 cell line 
(p < 0.05, by unpaired t-test). 
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Graph 5: The growth of embryonic kidney in an in vitro culture system 
treated with DOC-2 antibody (1:10). Error bar represents 
standard error of the mean. 
*，statistically significant difference was found between the 
control and treatment group (p < 0.01, by unpaired t-test). 
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Graph 6: p53 weighted scores for normal ovaries and various ovarian 
tumors. Numbers in parenthesis represent sample numbers. 
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Graph 7: Bcl-2 weighted scores for normal ovaries and various ovarian 
tumors. Numbers in parenthesis represent sample numbers. 
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Graph 8: Average weighted scores for the normal ovaries and various 
ovarian tumors which express bcl-2 and/or p53 proteins. 
Numbers in parenthesis represent sample numbers. 
Error bars represent standard error of Ae mean. 
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